TITLE:

COVID19-related and all-cause mortality among middle-aged and older adults across the first epidemic wave of SARS-COV-2 infection in the region of Tarragona, Spain: results from the COVID19 TARRACO Cohort Study, March-June 2020.

AUTHORS:

Angel Vila-Corcoles^{a,b}, Eva Satue-Gracia^{a,b}, Angel Vila-Rovira^b, Cinta de Diego-Cabanes^a, Maria Jose Forcadell-Peris^aandd Olga Ochoa-Gondar^{a,b}.

AFFILIATION:

^aPrimary Care Department Camp de Tarragona. Institut Catala de la Salut, Tarragona, Spain.

CORRESPONDENCE:

Olga Ochoa-Gondar. Unitat de Suport a la Recerca Tarragona-Reus. Institut Catala de la Salut C/ Rambla Nova 124, Tarragona 43001. Email: oochoa.tgn.ics@gencat.cat

^bUniversitary Institute of Primary Care Research IDIAP Jordi Gol. Barcelona, Spain.

SUMMARY

Background: Direct and indirect COVID19-related mortality is uncertain. This study

investigated COVID19-related and all-cause deaths among middle-aged and older adults during

the first wave of COVID19 epidemic period, assessing mortality risks by pre-existing socio-

demographic and medical underlying conditions.

Methods: Population-based cohort study involving 79,083 individuals ≥50 years-old in

Tarragona (Southern Catalonia, Spain). Baseline cohort characteristics (age/sex, comorbidities

and medications/vaccinations history) were established at study start (01/03/2020) and main

outcomes were COVID19-related deaths (occurred in patients diagnosed with the disease) and

all-cause deaths occurred among cohort members between 01/03/2020-30/06/2020. Mortality

risks were assessed by Cox regression analyses.

Results: Cohort members were followed for 1,356,358 persons-weeks, occurring 576 all-cause

deaths (124 COVID19-related). All-cause mortality rate was 42.5 deaths per 100,000 persons-

week, being 22.8 in healthy/unrelated-COVID19 subjects, 236.4 in COVID19-excluded/PCR-

negative subjects, 493.7 in COVID19-compatible/PCR-unperformed subjects and 4009.1 in

COVID19-confirmed patients. In multivariable analyses, increasing age, sex male, nursing-

home residence, cancer, neurologic, cardiac or liver disease, receiving diuretics, systemic

corticosteroids, proton-pump inhibitors and benzodiazepines were associated with increased

risk of all-cause mortality; conversely, receiving renin-angiotensin inhibitors and statins were associated with reduced risk. Age/years, sex male and nursing-home residence were strong

predictors for COVID19-related mortality, but none comorbidity appeared significantly

associated with an increased risk.

Conclusion: Apart from direct COVID19-related deaths (which represented almost 22% of all-

mortality), theoretically COVID19-excluded patients (PCR-negative)

considerable greater all-cause mortality than healthy/unrelated-COVID19 subjects, which could

explain, in part, the large excess deaths observed across the COVID19 pandemic.

KEYWORDS: Coronavirus, SARS-COV-2, COVID19, Mortality, Risk.

INTRODUCTION

A year ago, following an outbreak of pneumonia in Wuhan (China), a new coronavirus was detected. Said virus, later named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is the cause of the disease designated by the World Health Organization (WHO) as COVID19 in February 2020.[1] Currently, the pandemic caused by this virus continues to be a threat to public health worldwide.[2]

Available publications have reported different percentages of asymptomatic or mild cases of COVID19 but, even if they account for around 80%,[2,3] due to the high infectivity of the virus, the number of disease's related deaths is very high.[2] The mortality rates reported are very heterogeneous, depending on the countries (with important differences between regions, even within the same country), and also on the availability / policy of conducting diagnostic tests.[2]. For example, in Lombardy (Italy) the case fatality rate ranged between 1.6% and 18.3%,[4] while the Chinese Centre for Disease Control and Prevention, in a cohort of 72,314 cases, estimated a 2.3% case-fatality rate (14.8% for patients ≥80 years)[5]. Most articles report inhospital mortality or case fatality rates (mortality rate among confirmed cases); it must be taken into account that infection fatality rate (which consider all infected individuals) would be lower. On the other hand, many deaths from COVID19 occur in undiagnosed patients. Lastly, we have to keep in mind the "excess mortality" (deaths caused by other conditions, linked to a delay in care, overburden of the health system and socioeconomic determinants of health).[6,7]

In the case of Spain, the latest scientific-technical report of the Ministry of Health (dated November 12) informed a fatality rate of 11% in patients ≥50 years (reaching 19% in the group ≥70 years compared to 0.45% in aged 50-69 years).[8] However, the estimates that took into account the results of the seroprevalence study (done in May)[9] reported much lower rates: 0.04% in the younger (50-69 years) and 4.1% in those ≥70 years, with a global rate for ≥50 years of 1.5%.[8] According to the Statistics National Institute (INE), as compared with 2019, almost a 20% increased all-cause death occurred in Spain during 2020 (surely as consequence of COVID19 pandemic).[10]

Most reviews agree that age and gender are well-established risk factors of mortality in COVID19 patients,[11,12] but there is no clear consensus on the specific contribution of pre-existing conditions to the risk of mortality from the disease.[13] Knowing the relative contribution of factors related to the patient (including socio-demographic and medical aspects) to mortality is very important to identify the individuals with greater risk and guarantee a more efficient use of resources.

This study investigated COVID19-related and all-cause mortality among middle-aged and older adults in the region of Tarragona across the first epidemic wave (March-June 2020), assessing the possible association between previous conditions (demographic, comorbidities, chronic medications' use) and risk of death (COVID19-related and/or any cause) among middle-aged and older adults (who support the greatest burden of severe disease).

METHODS

Design, setting and study population

This is part of a large population-based retrospective-prospective cohort study (initiated in March 2020 and called *COVID19 TARRACO Cohort Study*) involving 79,083 individuals 50 years or older in the region of Tarragona (Southern Catalonia, Spain).

The design, setting and study population have been extensively described elsewhere, in prior articles that evaluated the epidemiology of COVID-19 during the first 8-12 weeks of epidemic period in the study area.[14,15]

The 79,083 cohort members were all individuals ≥50 years-old affiliated to the 12 Primary Care Centres (PCCs) managed by the *Institut Català de la Salut* in the study area (*Tarragonés, Alt Camp* and *Conca de Barberà* counties) and represented approximately 75% of overall inhabitants in this age strata according to census data.[16] This report focuses on cohort members who died (by COVID-19 or any cause) in the study setting between March 1 and June 30, 2020. The study was approved by the Ethical Committee of the Institution (Ethics Committee *IDIAP Jordi Gol*, Barcelona, file 20/065-PCV) and was conducted in accordance with the general principles for observational studies.[17] The study was determined to be exempt for informed consent under the public health surveillance exception.

Data sources

Former CAPAMIS Research Database, an institutional clinical database used for earlier cohort studies in the region,[18] was updated and exploited as the prime data source in this COVID-19 epidemiological report. Summarily, this database collects inputs from the electronic system (e-CAP) of primary care clinical records, that includes administrative and clinical data, coded according to the International Classification of Diseases 10th Revision (ICD-10). It allowed us to identify socio-demographic aspects and previous conditions/comorbidities among cohort members in order to define their baseline profile at study onset (01/03/2020).

Two new electronic alerts, related to COVID-19's laboratory results and ICD-10 codes for COVID-19 suspicion (B34.2, B97.29) were introduced to the e-CAP system at the beginning of the epidemic; later, both information sources were bonded to create the baseline research database utilised in this study.

Vital status was considered according to administrative data periodically updated in the e-CAP system. In addition, complementary data registered during emergency visits and/or hospital-stays, were used to complement vital status data in COVID-19 cases identified across study period. These data were transferred to a standardised form, after retrospective review of electronic records carried out by a research-trained group of family physicians and were afterwards linked with the prime research database containing baseline characteristics of 79,083 cohort members.

Outcome definitions

Primary outcome was death from any cause (COVID19-related or not) occurred among cohort members during the 4-month of study period (01/03/2020-30/06/2020). Laboratory-confirmed COVID-19 case was defined when a cohort member tested positive in SARS-COV-2 using Reverse Transcription-Polymerase Chain Reaction (RT-PCR) or serological tests, according institutional guidelines.[19] COVID19-related death was considered when the patient died from any cause within the first 30-days after the onset of the disease or at any time during hospital-stay. Death by COVID-19 (likely due to COVID-19) or death with COVID-19 (likely due to other concomitant causes) were differentiated according to family physician's criteria after checking hospital and primary care clinical records in each of deceased COVID19 cases.

Covariates

Baseline covariates were age, sex, type of residence (community-dwelling or nursing-home), vaccinations' history, previous comorbidities and chronic medications' use; they were considered according to data registered in the e-CAP system.

Criteria used to define comorbidities and chronic medication use are extensively described in an appendix elsewhere.[15] Unrecorded comorbidities, medications or vaccinations were considered as absent.

In addition, at the end of the study period, according to their COVID-19 relation, cohort members were classified as: COVID19-unrelated/healthy, COVID19-excluded (PCR/serological test performed with negative result), COVID19-compatible (clinical suspicion alone, without any test performed) and COVID19-confirmed (positive PCR or serological test).

Statistical analysis

Descriptive statistics of socio-demographic and clinical variables include frequencies/ percentages for categorical variables; and means/ standard deviations (SD) for continuous variables. Chi-squared or Fisher test (categorical variables) and Student's t test (continuous variables) were used for comparison of differences between groups.

Mortality Rates (MRs) for COVID19-related and all-cause deaths were calculated per 100,000 persons-week, considering in the denominator the sum of the persons-time contributed for each cohort member during the study period (17.4 weeks). The confidence intervals (CIs) for the MRs were calculated assuming a Poisson distribution for uncommon events.

Cox regression analyses were used to calculate unadjusted, age&sex-adjusted and multivariable-adjusted hazards ratios (HRs) and estimate the association between baseline conditions and the time to the first outcome (COVID19-related or all-cause death) occurred among cohort members throughout the study period (from 1st March to 30th June 2020). All exposure above mentioned covariates (i.e., age, sex, residence, comorbidities/underlying conditions, chronic medications' use and vaccinations' history) were considered for multivariable Cox models; the method to select a subset of covariates to include in final models was the purposeful selection.[20] Final models include both significant or confounder variables and all covariates judged clinically or epidemiologically relevant. We performed a main analysis including the total study cohort (N=79,083) and two subgroup analyses restricted to community-

dwelling individuals (N=77,669) and nursing-home residents (N=1414), which are shown in supplementary tables. The analyses were performed using IBM SPSS Statistics for Windows, version 24 (IBM Corp., Armonk, N.Y., USA); in all of them, statistical significance was set at p<0.05 (two-tailed).

RESULTS

The study cohort included 79,083 persons (37,626 [47.6%] men and 41,407 [52.4%] women), with a mean age of 65.8 years (SD: 11.3). By age groups, 42,684 (54%) were aged 50-64 years and 10,386 (13.1%) were aged 80 years or older. A total of 77,669 (98.2%) were community-dwelling and 1414 (1.8%) nursing-home residents.

Cohort members were observed for a total of 1,356,358 persons-weeks (1,335,069 for community-dwelling and 21,289 for nursing-home residents). An amount of 4113 (5.2%) of the 79,083 cohort members was tested for SARS-COV-2 infection across study period; 3577 (87%) were negative and 536 (13%) positive (345 in community-dwelling and 191 in nursing-home residents). Two hundred and eighty-three cohort members (280 community-dwelling and 3 nursing-home residents) had a suspected COVID-19 without PCR testing (Table 1).

Across the four-month study period, 576 all-cause deaths were observed (413 in community-dwelling and 163 in nursing-home residents), of which 124 occurred among laboratory-confirmed COVID19 patients and were considered COVID19-related deaths (63 in community-dwelling and 61 in nursing-home residents). Of these 124 deceased patients with laboratory-confirmed COVID19, 112 (90.3%) died by (due to) COVID-19, while 12 (9.7%) died with COVID19 but likely due to other causes according to physician reviewers' criteria after checking clinical records (ten cases in community dwelling and two cases in nursing-home residents).

All-cause mortality rate was 42.5 deaths per 100,000 persons-week (95% CI: 39.2-46.1) considering the total study cohort. By residence, it was 30.9 per 100,000 persons-week (95% CI: 28.0-34.1) in community-dwelling and 765.7 per 100,000 persons-week (95% CI: 653.9-896.6) in nursing-home residents.

COVID19-related mortality rate was 9.1 per 100,000 persons-week considering the total study cohort, being 4.7 per 100,000 persons-week among community-dwelling and 286.5 per 100,000 persons-week among nursing-home residents. Therefore, deaths from COVID19 represented a 21.5% (124/576) of the overall deaths observed in the total study cohort (15.3% [63/413] in community-dwelling vs 37.4% [61/163] in nursing-home residents).

Of the 576 all-cause deaths, 295 occurred among the 74,687 COVID19-unrelated/ healthy subjects (22.8 deaths per 100,000 persons-week), 150 among the 3577 COVID19-excluded/PCR-negative subjects (236.4 deaths per 100,000 persons-week), 7 among the 283 COVID19-suspected/PCR-unperformed (493.7 deaths per 100,000 persons-week) and 124 among the 536 COVID19-confirmed subjects (4009.1 deaths per 100,000 persons-week) (Table 2).

Table 3 shows univariate analyses reporting all-cause deaths (n=576) by age, sex and preexisting conditions (comorbidities, chronic medications' use and vaccinations' history) in the total study cohort. Table 4 reports it for COVID19-related deaths (n=124). Tables 5 and 6 show Cox regression analyses assessing unadjusted, age&sex-adjusted and multivariable-adjusted risks of suffer all-cause death and COVID19-related death, respectively, in the total study cohort.

Supplementary tables S1-S4 show subgroup analyses restricted to community-dwelling individuals and supplementary tables S5-S8 show subgroup analyses restricted to nursing-home residents.

After multivariable-adjustments assessing risks of all-cause mortality in the total study cohort (see Table 5), increasing age/years (HR: 1.08; 95% CI: 1.07-1.09; p<0.001), male sex (HR: 1.47; 95% CI: 1.24-1.79; p<0.001), nursing-home residence (HR: 1.63; 95% CI: 1.28-2.09; p<0.001), neurological disease (HR: 1.48; 95% CI: 1.18-1.85; p=0.001), cancer (HR: 2.46; 95% CI: 2.03-2.98; p<0.001), cardiac disease (HR: 1.29; 95% CI: 1.06-1.56; p=0.009), liver disease (HR: 1.76; 95% CI: 1.14-2.73; p=0.012), receiving diuretics (HR: 1.55; 95% CI: 1.27-1.88; p<0.001), systemic corticosteroids (HR: 3.49; 95% CI: 2.59-4.70; p<0.001), proton-pump inhibitors (HR: 1.25; 95% CI: 1.03-1.51; p=0.026) and benzodiazepines (HR: 1.34; 95% CI: 1.11-1.61; p=0.003) were associated with a significant increased risk. Conversely, receiving Angiotensin Converting Enzyme inhibitors (ACEIs) (HR: 0.73; 95% CI: 0.60-0.88; p=0.001), Angiotensin II Receptor Blockers (ARBs) (HR: 0.59; 95% CI: 0.46-0.77; p<0.001) and statins (HR: 0.72; 95% CI: 0.59-0.88; p=0.002) were associated with a reduced risk. In subgroup analyses restricted to community-dwelling individuals, the results did not substantially change (see supplementary Table S3). In subgroup analysis restricted to nursing-home residents (see supplementary Table S7), history of tetanus vaccination was associated with a reduced risk (HR: 0.65; 95% CI: 0.44-0.97; p=0.036).

If we consider COVID19-related mortality (see Table 6), many comorbidities (cancer, neurological, renal, respiratory, cardiac disease, diabetes and hypertension) appeared associated with an increased risk in the crude analyses. However, after age&sex-adjustment only neurological, respiratory and cardiac disease were associated with increased risk, and none of them appeared significantly associated with an increased risk after multivariable-adjustment. In this analysis, increasing age/years (HR: 1.08; 95% CI: 1.06-1.10; p<0.001), male sex (HR: 1.82; 95% CI: 1.24-2.70; p=0.003) and nursing-home residence (HR: 12.56; 95% CI: 8.07-19.54; p<0.001) were the strongest predictors for COVID19-related mortality. Considering chronic medications' use, while many medications were associated with an increased risk in crude analyses, none of them altered the risk of COVID19-related death in multivariable analysis (except for ARBs [HR: 0.52; 95% CI: 0.26-1.01; p=0.054] and oral antidiabetic drugs [HR: 2.14; 95% CI: 1.03-4.43; p=0.042], that were marginally associated with reduced and increased risk, respectively).

In subgroup analyses restricted to community-dwelling individuals evaluating risk of COVID19-related mortality, besides age/years and male sex, taking diuretics (HR: 1.89; 95% CI: 1.03-3.46; p=0.041) and systemic corticosteroids (HR: 3.10; 95% CI: 1.27-7.59; p=0.013) emerged associated with increased risk. None other medication, comorbidity and/or vaccination's history

altered the risk of COVID19-related death after multivariable-adjustments in these community-dwelling individuals (see supplementary Table S4).

In subgroup analyses restricted to nursing-home residents, apart from increasing age and male sex, only receiving antineoplastic agents (HR: 3.81; 95% CI: 1.00-14.44; p=0.049) and, surprisingly, influenza vaccination in prior autumn (HR: 2.34; 95% CI: 1.08-5.07; p=0.031) significantly altered the risk of COVID19-related death after multivariable adjustment (see supplementary Table S8).

DISCUSSION

Direct and indirect mortality due to COVID19 is controversial.[4,5,8,11,13,21,22] This study investigated all-cause and COVID19-related deaths among middle-aged and older adults in the region of Tarragona (Southern Catalonia, Spain) across the first wave of COVID19 epidemic period (March-June 2020), assessing mortality risks by demographic characteristics and underlying medical conditions. Of note, the study was conducted in a region with relatively low incidence of COVID19 as compared with other European and Spanish regions.[2,3,8]

As main findings, all-cause mortality rate across study period was 42.5 deaths per 100,000 persons-week, and COVID19-related deaths represented 21.5% of overall deaths. Considering specifically COVID19-related deaths (those occurred among patients with laboratory-confirmed COVID19), 90.3% died by COVID-19 and 9.7% died with COVID19 (i.e., the death may be attributed to other baseline or concomitant cause.

Increasing age, male sex, and nursing-home residence appear as the strongest predictors for both COVID19-related death and all-cause death. Other pre-existing conditions may also alter mortality risk, especially some comorbidities and chronic medications' use, which emerged significantly related with all-cause mortality risk.

Importantly, apart from COVID19-related deaths (occurring among patients with laboratory-confirmed COVID19), theoretically COVID19-excluded patients (i.e., those persons with a negative PCR) suffered ten times greater all-cause mortality than unrelated-COVID19/healthy subjects. This fact suggests that, apart from baseline excess risk in PCR-negative subjects (who were older and had more comorbidities than healthy/COVID19-unrelated subjects), some of the observed excess mortality in PCR-negative subjects could be due to undiagnosed/undetected COVID19 despite PCR performed. In this sense, we note that the reliability of PCR testing depends on the quality of the nasopharyngeal samples collected, timing of collection and sensitivity of tests used,[19] which could explain, in part, the excess all-cause mortality observed in PCR-negative subjects in this study.

Regarding excess mortality, the Statistics National Institute (INE) reported an increase in deceases in 2020 (compared to 2019) of 18.95%; which corresponds in absolute numbers to 70,715 deaths, of which only 43,131 were attributed to COVID19.[10] The considerably larger all-cause mortality in PCR-negative subjects observed in the present study may reflect

COVID19 underdiagnosis and could explain, in part, some excess all-cause deaths observed across the current COVID19 pandemic.

We note the importance of providing adjusted data instead of crude data. Thus, while crude all-cause mortality rate was almost 25-times greater in nursing-home (766 deaths per 100,000 persons-week) than in community-dwelling individuals (31 deaths per 100,000 persons-week), we found that after multivariable adjustments (by age/sex and pre-existing conditions) nursing-home residence only increased approximately 1.6 times the adjusted risk of all-cause mortality (HR: 1.63; 95% CI: 1.28-2.09) as compared with community-dwelling. In this same way, apart from increasing age and sex male, many pre-existing conditions appeared significantly associated with an increased risk of COVID19-related mortality in the crude analysis (and several in the age&sex-adjusted analysis), but none comorbidity emerged significantly associated with an increased risk after multivariable adjustment.

This highlights the importance of maximizing adjusted data assessing event's risk in observational studies. In fact, this could explain distinct/opposite data reported in different studies evaluating relationships between some pre-existing comorbidities/conditions and susceptibility/risk of suffering COVID19 infection or death.[4,5,11,13, 21-26] To illustrate it, besides subgroup analyses, we reported all unadjusted, age&sex-adjusted and multivariable-adjusted results here, which is a major strength in this study.

Considering chronic medication, there is scarce data reporting the possible influence of previous use of these drugs on the risk of COVID19-related mortality. We did not observe any significant association in this sense but, interestingly, receiving statins and renin-angiotensin inhibitors were significantly associated with a lower risk of all-cause mortality in our study cohort.

Major strengths in this study were the large size and representativity of the cohort (that included more than 79,000 people, which represents approximately 75% of overall population over 50 years of age in the study area, and the use of survival analysis methods to accurately estimate both risks of all-cause and COVID19-related mortality by distinct important population subgroups (based in its relation with COVID19): COVID19-confirmed subjects, COVID19-suspected subjects (without PCR performed), COVID19-excluded subjects (negative PCR testing) and COVID19-unrelated/healthy subjects). The large size of the study cohort together with the adjustment of major possible confounding variables (e.g., age, type of residence, pre-existing underlying conditions/comorbidities and chronic medications' use) in the multivariable analyses may provide an acceptable basis to assess mortality risk among the general population ≥50 years across the first wave of COVID19 epidemic period in our setting.

Major limitations in this study are related with its retrospective design and scarce availability of PCR tests during the first weeks of study period. Indeed, considering that PCR testing was not routinely performed for all clinically compatible/suspected COVID19 patients across the study period, the laboratory-confirmed COVID19 cases (and, consequently, the number of COVID19-related deaths) were likely underestimated. Then, all-cause mortality (which is not influenced by the frequency of PCR testing) may be a better measure of COVID19 pandemic impact. As another limitation, the study was conducted in a single geographical area and, logically, specific

mortality data may not be directly extrapolated to other geographical regions with distinct epidemic conditions.

The authors recognise these inherent limitations but note that, opposite to many papers reporting only crude COVID19 data, the present study provides age&sex-adjusted and multivariable-adjusted data evaluating both all-cause and COVID19-related mortality risks. Importantly, the estimations may considerably vary depending on type of analyses/adjustments performed; therefore, we underline again the importance of maximizing adjustments. We did subgroup analysis (nursing-home/community-dwelling) and multivariable-adjustments, but, as in all observational studies, a residual confounding due to unmeasured factors (e.g., socio-economical, lifestyle, job- or healthcare-related factors) cannot be excluded.

CONCLUSIONS

In summary, in this large cohort study including 79,083 middle-aged and older adults followed across the first wave of COVID19 epidemic period in the region of Tarragona, we found that deaths from COVID19 represented 21.5% of all-cause mortality occurred across study period (March-June 2020). Increasing age, sex male, nursing-home residence, cancer, neurologic, cardiac or liver disease, receiving diuretics, systemic corticosteroids, proton-pump inhibitors and benzodiazepines were associated with an increased risk of all-cause mortality; conversely, receiving renin-angiotensin inhibitors and statins were associated with a reduced risk. Age/years, sex male and nursing-home residence were strong predictors for COVID19-related mortality, but no comorbidity was independently associated with increased risk.

Interestingly, apart from COVID19-related deaths (approximately 10% of them could be attributed to another baseline or concomitant cause), theoretically COVID19-excluded patients (PCR-negative) suffered considerable greater all-cause mortality than healthy/unrelated-COVID19 subjects. This data suggests COVID19 underdiagnosis and it could explain, in part, the unexpected excess deaths observed during the COVID19 pandemic.

CONTRIBUTORS: AVC designed the study; AVC and ESG assessed outcomes and wrote the manuscript; ESG, CDC and MFP obtained data; ESG and AVR did statistical analyses and edited the manuscript; OOG revised the final version; AVC coordinated the study.

FUNDING: This study is supported by a grant from the Instituto de Salud Carlos III of the Spanish Health Ministry (file COV20/00852; call for the SARS-COV-2/COVID-19 disease, RDL 8/2020, March 17, 2020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

COMPETING INTEREST: All authors, none declared.

REFERENCES

- 1. World Health Organization (WHO). Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. Available at: http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed December 9, 2020).
- 2. European Centre for Disease Prevention and Control. Novel coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK—sixth update—12 March 2020. Stockholm: ECDC: 2020.
- 3. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 2020;17(9):e1003346. Published 2020 Sep 22. doi:10.1371/journal.pmed.1003346
- 4. Odone A., Delmonte D., Scognamiglio T., Signorelli C. COVID-19 deaths in Lombardy, Italy: data in context. Lancet Public Heal. 2020:5. doi: 10.1016/S2468-2667(20)30099-2.
- 5. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020; 180:934.
- 6. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584:430.
- 7. Gold JAW, Rossen LM, Ahmad FB, et al. Race, Ethnicity, and Age Trends in Persons Who Died from COVID-19 United States, May-August 2020. MMWR Morb Mortal Wkly Rep 2020; 69:1517.
- 8. Gobierno de España. Secretaría General de Sanidad y Consumo. Dirección General de Salud Pública, Calidad e innovación. Centro de Coordinación de Alertas y Emergencias Sanitarias. Información científica-técnica. Enfermedad por coronavirus, COVID-19 Actualización de noviembre, 2020. Available at: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/I TCoronavirus.pdf. (Accessed December 5, 2020).
- 9. Instituto de Salud Carlos III. Estudio ENE-COVID19: informe final. Estudio nacional de sero-epidemiología de la infección por SARS-CoV-2 en España. July 6, 2020. Available at: https://www.mscbs.gob.es/ciudadanos/ene-covid/docs/ESTUDIO_ENE-COVID19_INFORME_FINAL.pdf. (Accessed December 5, 2020).
- 10. Instituto Nacional de Estadística (INE). Estimación del número de defunciones semanales durante el brote de COVID-19. Available at: https://www.ine.es/experimental/defunciones/experimental_defunciones.htm. (Accessed December 5, 2020).
- 11. Figliozzi S, Masci PG, Ahmadi N, et al. Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. Eur J Clin Invest. 2020;50(10):e13362. doi:10.1111/eci.13362.
- 12. Verity R, Okell LC, Dorigatti I, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis 2020; 20:669.
- 13. Ejaz H, Alsrhani A, Zafar A, et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833-1839. doi:10.1016/j.jiph.2020.07.014.
- 14. Vila-Córcoles Á, Ochoa-Gondar O, Torrente-Fraga C, et al. Evaluación de la incidencia y perfil de riesgo de Covid-19 según comorbilidad previa en adultos ≥50 años del área de Tarragona. Rev Esp Salud Pública 2020; 94: e202006065.
- 15. Vila-Córcoles A, Ochoa-Gondar O, Satué-Gracia EM, et al. Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona, Spain. BMJ Open. 2020 Dec 10;10(12):e041577.
- 16. IDESCAT. Statistical Institute of Catalonia. Available at: https://www.idescat.cat/?lang=en. (Accessed December 20, 2020]
- 17. World Medical Association. WMA Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. Available at: https://www.wma.net/policies-post/wmadeclaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. (Accessed December 20, 2020).
- 18. Vila-Corcoles A, Hospital-Guardiola I, Ochoa-Gondar O, et al. Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke. BMC Public Health. 2010;10:25.
- 19. Generalitat de Catalunya. Subdirecció General de Vigilància i Resposta a Emergències de Salut Pública. Procediment d'actuació enfront de casos d'infecció pel nou coronavirus SARSCoV-2. Available at: https://canalsalut.gencat.cat/web/.content/_A-Z/C/coronavirus-2019-ncov/material-divulgatiu/procediment-actuacio-coronavirus.pdf (Accessed December 20, 2020)

- 20. Hosmer DW, Lemeshow S. Applied Survival Analysis. Regression Modeling of Time to Event Data. New York: John Wiley & Sons, 1999.
- 21. Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020; 94: 91-95.
- 22. Ssentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. PLoS One. 2020;15(8):e0238215.
- 23. Liang WH, Guan WJ, Li CC, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicenter) and outside Hubei (non-epicenter): A Nationwide Analysis of China. Eur Respir J. 2020: 2000562.
- 24. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020; 323:1574 1581.
- 25. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054-62.
- 26. Deng G, Yin M, Chen X, Zeng F. Clinical determinants for fatality of 44,672 patients with COVID-19. CritCare. 2020; 24:179.

TABLES

Table 1. Distribution of study population according to Covid19 related status at the end of study period. Population over 50 years, Tarragona region (Southern Catalonia, Spain), 01/03/2020-30/06/2020.

30/06/2020.	001/1546	00\/'540	00\/'540	00\/'546	
COVID19 related status	COVID19	COVID19	COVID19	COVID19	
	Nonrelated	Excluded	Suspected	Confirmed	
	(Healthy)	(PCR-)	(Without PCR)	(PCR+)	
Characteristic	N=74687	N=3577	N=283	N=536	n value
Characteristic	n (%)	n (%)	n (%)	n (%)	p-value
Sociodemographical	05.5 (44.4)	70.0 (40.0)	00.0 (0.4)	74.0 (44.0)	0.004
Age: years, sd	65.5 (11.1)	70.0 (12.8)	60.6 (9.4)	74.0 (11.3)	<0.001
Age group: 50-64 yrs	40799 (54.6)	1492 (41.7)	216 (76.3)	177 (33.0)	<0.001
65-79 yrs	24638 (33.0)	1186 (33.2)	52 (18.4)	137(25.6)	
≥80 yrs Sex Men	9250 (12.4)	899 (25.1)	15 (5.3)	222 (41.4)	0.000
Women	35575 (47.6)	1701 (47.6)	115 (40.6)	235 (43.8)	0.036
Community-dwelling	39112 (52.4)	1876 (52.4)	168 (59.4)	301(56.2)	-0.004
Nursing-home residence	73870 (98.9) 817 (1.1)	3174 (88.7)	280 (98.9)	345 (64.4) 191 (35.6)	<0.001
Comorbidities	017 (1.1)	403 (11.3)	3 (1.1)	191 (33.6)	
	400F (0.C)	202 (0.2)	10 (2.5)	70 (44.7)	-0.004
Neurological disease	1935 (2.6)	293 (8.2)	10 (3.5)	79 (14.7)	<0.001
Renal disease	3982 (5.3)	420 (11.7)	9 (3.2)	65 (12.1)	<0.001
Cancer	5995 (8.0)	549 (15.3)	19 (6.7)	67 (12.5)	<0.001
Rheumatic disease	804 (1.1)	57 (1.6)	4 (1.4)	7 (1.3)	0.032
Inflammatory bowel disease	497 (0.7)	27 (0.8)	2 (0.7)	6 (1.1)	0.567
Respiratory disease	6592 (8.8)	567(15.9)	33 (11.7)	80 (14.9)	<0.001
Cardiac disease	12232 (16.4)	1016 (28.4)	34 (12.0)	153 (28.5)	<0.001
Atrial fibrillation	3317 (4.4)	392 (11.0)	7 (2.5)	70 (13.1)	<0.001
Liver disease	1338 (1.8)	110 (3.1)	6 (2.1)	11 (2.1)	<0.001
Diabetes	12322 (16.5)	838 (23.4)	31 (11.0)	126 (23.5)	<0.001
Hypertension	32604 (43.7)	1937 (54.2)	114 (40.3)	290 (54.1)	<0.001
Hypercholesterolemia	25638 (34.3)	1398 (39.1)	97 (34.3)	181 (33.8)	<0.001
Obesity	20468 (27.4)	1013 (28.3)	62 (21.9)	135 (25.2)	0.068
Smoking	12074 (16.2)	591 (16.5)	44 (15.5)	41 (7.6)	<0.001
Alcoholism	1644 (2.2)	134 (3.7)	7 (2.5)	11 (2.1)	<0.001
Chronic medications use				-	ı
Diuretics	7586 (10.2)	731 (20.4)	25 (8.8)	139 (25.9)	<0.001
Beta blockers	8817 (11.8)	632 (17.7)	35 (12.4)	87 (16.2)	<0.001
ACEIs	15374 (20.6)	872 (24.4)	59 (20.8)	114 (21.3)	<0.001
ARBs	8317 (11.1)	471 (13.2)	27 (9.5)	54 (10.1)	0.001
Calcium channel blockers	5990 (8.0)	420 (11.7)	16 (5.7)	64 (11.9)	<0.001
Statins	15063 (20.2)	936 (26.2)	44 (15.5)	91 (17.0)	<0.001
Oral anticoagulants	3461 (4.6)	385 (10.8)	8 (2.8)	58 (10.8)	<0.001
Antiplatelet drugs	8344 (11.2)	676 (18.9)	26 (9.2)	108 (20.1)	<0.001
Insulin	2726 (3.6)	271 (7.6)	2 (0.7)	43 (8.0)	<0.001
Oral antidiabetic drugs	9855 (13.2)	623 (17.4)	22 (7.8)	85 (15.9)	<0.001
Inhaled respiratory drugs	5628 (7.5)	552 (15.4)	36 (12.7)	77 (14.4)	<0.001
Antineoplastic agents	104 (0.1)	12 (0.3)	0 (0.0)	0 (0.0)	0.017
Systemic corticosteroids	1105 (1.5)	130 (3.6)	7 (2.5)	10 (1.9)	<0.001
NSADs	4079 (5.5)	191 (5.3)	30 (10.6)	21 (3.9)	0.001
Chloroquine	154 (0.2)	11 (0.3)	2 (0.7)	1 (0.2)	0.176
Antihistamines	3085 (4.1)	152 (4.2)	12 (4.2)	15 (2.8)	0.469
Proton-Pump Inhibitors	16254 (21.8)	1423 (39.8)	71 (25.1)	183 (34.1)	<0.001
Benzodiazepines	12026 (16.1)	819 (22.9)	75 (26.5)	126 (23.5)	<0.001
Vaccination's history	· ,	· ·			
Flu vaccine in prior autumn	20838 (27.9)	1449 (40.5)	61 (21.6)	258 (48.1)	<0.001
PPV23	24189 (32.4)	1666 (46.6)	56 (19.8)	272 (50.7)	<0.001
PCV13	1005 (1.3)	108 (3.0)	8 (2.8)	18 (3.4)	<0.001
Tetanus	47761 (63.9)	2507 (70.1)	187 (66.1)	344 (64.2)	<0.001
	\ '-/	` '	` '	` /	I .

NOTE: P-values were calculated by Chi-squared or Fisher's test as appropriate.

Table 2. Distribution of all-cause deaths according to COVID19-related status in cohort members. Tarragona, 01/03/2020-30/06/2020.

Mortality	No. of	Persons-time follow-up	No. of	Mortality Rate
Population	persons	(No. of persons-week)	deaths	MR (95% CI)
ALL PERSONS	79,083	1356358	576	42.5 (39.2-46.1)
Healthy (non-related COVID19)	74,687	1290922	290	22.5 (20.1-25.2)
COVID19-excluded (PCR-)	3577	60825	145	238.4 (201.2-282.3)
COVID19-suspected (non-PCR tested)	283	1518	7	493.7 (198.0-1017.0)
COVID19-confirmed (PCR+)	536	3093	124	4009.1 (3339.6-4810.9)
COMMUNITY-DWELLING	77,669	1335069	413	30.9 (28.0-34.1)
Healthy (non-related COVID19)	73,870	1277550	228	17.8 (15.7-20.2)
COVID19-excluded (PCR-)	3174	54077	117-3	216.4 (180.3-259.7)
COVID19-suspected (non-PCR tested)	280	1503	3-3	199.6 (41.1-582.8)
COVID19-confirmed (PCR+)	345	1938	63	3250.8 (2503.1-4226.0)
NURSING-HOME	1414	21289	163	765.7 (653.9-896.6)
Healthy (non-related COVID19)	817	13371	67	501.1 (393.4-636.4)
COVID19-excluded (PCR-)	403	6747	33-2	489.1 (340.9-679.8)
COVID19-suspected (non-PCR tested)	3	15	2-2	13333.3 (1613.3-48133.2)
COVID19-confirmed (PCR+)	191	1155	61	5281.4 (4066.7-6865.8)

NOTE: MR denotes mortality rate, and it's calculated for 100,000 persons-week. CI denotes confidence interval.

Table 3. Incidence of all-cause mortality according to baseline demographical and clinical characteristics (comorbidities/medications) in the total study cohort (N=79,083). Tarragona

region (Southern Catalonia, Spain), 01/03/2020-30/06/2020. All-cause deaths (n=576) Study population Characteristic Mortality rate (N=79083)Univariate analysis Time follow-up n (%) n (%) p-value (persons-week) MR* (95% CI) Sociodemographical Age: 50-64 vrs 42684 (54.0) 54 (9.4) < 0.001 734123 7.4 (5.5-9.8) 33.3 (28.1-39.4) 65-79 yrs 26013 (32.9) 149 (25.9) 447474 10386 (13.1) 213.4 (191.8-237.3) ≥80 vrs 373 (64.8) 174761 Sex Men 37626 (47.6) 302 (52.4) 0.019 645470 46.8 (41.7-52.5) Women 41457 (52.4) 274 (47.6) 710888 38.5 (34.0-43.7) Community-dwelling 77676 (98.2) 413 (71.7) < 0.001 1335069 30.9 (28.0-34.1) **Nursing-home residence** 1407 (1.8) 163 (28.3) 21289 765.7 (653.9-896.6) Comorbidities Neurological disease 2317 (2.9) 119 (20.7) < 0.001 38344 310.3 (258.5-372.4) Renal disease 4476 (5.7) 134 (23.3) < 0.001 75629 177.2 (149.6-209.8) Cancer 6630 (8.4) 168 (29.2) < 0.001 112481 149.4 (127.6-174.9) Rheumatic disease 872 (1.1) 10 (1.7) 0.144 14897 67.1 (32.2-123.5) Inflammatory bowel disease 532 (0.7) 8 (1.4) 0.035 9097 87.9 (37.9-173.2) Respiratory disease 7272 (9.2) 129 (22.4) < 0.001 123794 104.2 (86.8-125.0) Cardiac disease 13435 (17.0) 263 (45.7) < 0.001 228716 115.0 (101.4-130.4) Atrial fibrillation 3786 (4.8) 114 (19.8) < 0.001 63962 178.2 (148.4-213.8) 1465 (1.9) Liver disease 22 (3.8) < 0.001 24998 88.0 (55.2-132.9) **Diabetes** 13317 (16.8) 183 (31.8) < 0.001 227640 80.4 (69.3-93.3) Hypertension 34945 (44.2) 406 (70.5) < 0.001 597890 67.9 (61.5-75.0) Hypercholesterolemia 27314 (34.5) 228 (39.6) 0.011 468535 48.74 (43.0-55.2) 21678 (27.4) Obesity 151 (26.2) 0.518 372086 40.6 (34.7-47.5) **Smoking** 12750 (16.1) 60 (10.4) < 0.001 219518 27.3 (21.0-35.5) **Alcoholism** 1796 (2.3) 17 (3.0) 0.271 30774 55.2 (32.2-88.3) Chronic medications use **Diuretics** 8481 (10.7) 238 (41.3) < 0.001 143357 166.0 (146.4-188.2) Beta blockers 9571 (12.1) 138 (24.0) < 0.001 163450 84.4 (71.2-99.9) **ACEIS** 16419 (20.8) 142 (24.7) 0.021 281514 50.4 (42.5-59.7) **ARBs** 8869 (11.2) 64 (11.1) 0.937 152376 42.0 (32.3-54.6) Calcium channel blockers 6490 (8.2) 71 (12.3) < 0.001 111107 63.9 (50.2-81.2) **Statins** 16134 (20.4) 123 (21.4) 0.569 44.4 (37.0-53.3) 277237 **Oral anticoagulants** 135.5 (109.6-168.0) 3912 (4.9) 90 (15.6) < 0.001 66424 **Antiplatelet drugs** 9154 (11.6) 173 (30.0) < 0.001 155957 110.9 (95.6-128.6) 116.0 (89.3-150.8) Insulin 3042 (3.8) 60 (10.4) < 0.001 51741 Oral antidiabetic drugs 10585 (13.4) 123 (21.4) < 0.001 181452 67.8 (56.5-81.4) Inhaled respiratory drugs 6293 (8.0) 125 (21.7) < 0.001 106857 117.0 (97.5-140.4) Antineoplastic agents 1614 (2.0) 16 (2.8) 0.209 57.8 (33.1-93.6) 27691 Systemic corticosteroids 1252 (1.6) 56 (9.7) < 0.001 21030 266.3 (205.1-346.2) **NSADs** 4321 (5.5) 10 (1.7) < 0.001 74152 13.5 (6.5-24.8) Chloroquine 168 (0.2) 0 (0.0) 0.266 2867 **Antihistamines** 19.6 (9.8-35.1) 3264 (4.1) 11 (1.9) 0.007 56243 **Proton-Pump Inhibitors** 17931 (22.7) 312 (54.2) < 0.001 305566 102.1 (91.1-114.5) Benzodiazepines 13046 (16.5) 166 (28.8) < 0.001 222537 74.6 (63.7-87.4) Vaccination's history Flu vaccine in prior autumn 355 (61.6) < 0.001 92.0 (82.7-102.3) 22606 (28.6) 385668 PPV23 26183 (33.1) 395 (68.6) < 0.001 447270 88.3 (80.0-97.5) PCV13 24 (4.2) < 0.001 19272 1139 (1.4) 124.5 (79.8-185.5) 50799 (64.2) 415 (72.0) < 0.001 871204 47.6 (43.1-52.6)

> NOTE: P-values in univariate analysis were calculated by chi-squared, or Fisher's test as appropriate, comparing percentages in the study population vs all-cause deaths cases; MR denotes mortality rates per 100.000 persons-week; Cls denotes confidence intervals for mortality rates and were calculated assuming a Poisson distribution for uncommon events.

Tetanus

Table 4. Incidence of Covid19-related mortality according to baseline demographical and clinical characteristics (comorbidities/medications) in the total study cohort (N=79,083). Tarragona region (Southern Catalonia, Spain), 01/03/2020-30/06/2020.

COVID-19 deaths (n=124) Study population Time follow-up Characteristic (N=79083)Univariate analysis Mortality rate n (%) p-value n (%) (persons-week) MR* (95% CI) Sociodemographical 0.4 (0.1-1.2) Age: 50-64 vrs 42684 (54.0) 3(2.4) < 0.001734123 65-79 yrs 26013 (32.9) 35 (28.2) 447474 7.8 (5.4-10.8) 10386 (13.1) 86 (69.4) ≥80 vrs 174761 49.2 (39.8-61.0) Sex Men 37626 (47.6) 63 (50.8) 0.471 645470 9.8 (7.5-12.7) Women 41457 (52.4) 61 (49.2) 710888 8.6 (6.6-11.2) Community-dwelling 77676 (98.2) 63 (50.8) < 0.001 1335069 4.7 (3.6-6.1) Nursing-home residence 1407 (1.8) 61 (49.2) 21289 286.5 (220.6-372.5) Comorbidities 29 (23.4) < 0.001 Neurological disease 2317 (2.9) 38344 75.6 (50.7-108.9) Renal disease 4476 (5.7) 23 (18.5) < 0.001 75629 30.4 (19.3-45.6) Cancer 6630 (8.4) 23 (18.5) < 0.001 112481 20.4 (12.9-30.6) Rheumatic disease 872 (1.1) 0 (0.0) 0.239 14897 Inflammatory bowel disease 532 (0.7) 2 (1.6) 0.200 9097 22.0 (2.7-79.4) Respiratory disease 7272 (9.2) 27 (21.8) < 0.001 123794 21.8 (14.4-31.8) Cardiac disease 13435 (17.0) 54 (43.5) < 0.001 228716 23.6 (17.5-31.2) Atrial fibrillation 3786 (4.8) 23 (18.5) < 0.001 63962 36.0 (22.8-54.0) Liver disease 1465 (1.9) 3 (2.4) 0.639 24998 12.0 (2.5-35.0) **Diabetes** 13317 (16.8) 41 (33.1) < 0.001 227640 18.0 (12.9-24.5) 13.2 (10.5-16.5) Hypertension 34945 (44.2) 79 (63.7) < 0.001 597890 Hypercholesterolemia 27314 (34.5) 48 (38.7) 0.328 468535 10.2 (7.6-13.5) 30 (24.2) 0.421 Obesity 21678 (27.4) 372086 8.1 (5.5-11.6) **Smoking** 12750 (16.1) 11 (8.9) 0.028 219518 5.0 (2.5-9.0) Alcoholism 1796 (2.3) 3 (2.4) 0.912 30774 9.7 (2.0-28.3) Chronic medications use **Diuretics** 8481 (10.7) 49 (39.5) < 0.001 143357 34.2 (25.4-45.1) Beta blockers 9571 (12.1) 29 (23.4) < 0.001 163450 17.7 (11.9-25.5) **ACEIs** 16419 (20.8) 32 (25.8) 0.166 281514 11.4 (7.7-16.3) **ARBs** 8869 (11.2) 11 (8.9) 0.408 152376 7.2 (3.6-12.9) Calcium channel blockers 6490 (8.2) 18 (14.5) 0.010 111107 16.2 (9.6-25.6) 16134 (20.4) 26 (21.0) 0.876 Statins 277237 9.4 (6.1-13.8) Oral anticoagulants 3912 (4.9) 17 (13.7) 0.001 25.6 (14.9-41.0) 66424 Antiplatelet drugs 9154 (11.6) 35 (28.2) < 0.001 155957 22.4 (15.6-31.1) 51741 Insulin 3042 (3.8) 12 (9.7) 0.001 23.2 (12.0-40.6) Oral antidiabetic drugs 10585 (13.4) 33 (26.6) < 0.001 181452 18.2 (12.7-25.3) Inhaled respiratory drugs 6293 (8.0) 28 (22.6) < 0.001 106857 26.2 (17.4-38.0) Antineoplastic agents 1614 (2.0) 4 (3.2) 0.350 27691 14.4 (3.9-36.9) Systemic corticosteroids 1252 (1.6) 6 (4.8) 0.004 21030 28.5 (10.5-62.1) **NSADs** 4321 (5.5) 0 (0.0) 0.007 74152 0 (0.0) 0.607 Chloroquine 168 (0.2) 2867 **Antihistamines** 3264 (4.1) 0 (0.0) 0.021 56243 **Proton-Pump Inhibitors** 17931 (22.7) 56 (45.2) < 0.001 305566 18.3 (14.1-23.8) Benzodiazepines 13046 (16.5) 37 (29.8) < 0.001 222537 16.6 (11.6-23.1) Vaccination's history 22606 (28.6) 88 (71.0) < 0.001 Flu vaccine in prior autumn 385668 22.8 (18.4-28.3) PPV23 26183 (33.1) 86 (69.4) < 0.001 447270 19.2(15.5-23.8) PCV13 1139 (1.4) 4 (3.2) 0.095 19272 20.8 (5.7-53.2) Tetanus 50799 (64.2) 82 (66.1) 0.660 871204 9.4 (7.5-11.8)

NOTE: P-values in univariate analysis were calculated by chi-squared, or Fisher's test as appropriate, comparing percentages in the study population vs Covid19-related cases; MR denotes mortality rates per 100.000 persons-week; CIs denotes confidence intervals for mortality rates and were calculated assuming a Poisson distribution for uncommon events.

Table 5. Cox regression analyses assessing unadjusted, age & sex-adjusted and multivariable-adjusted risk of all-cause mortality in the total study cohort (N=79,083). Tarragona region (Southern Catalonia, Spain) from 01/03/2020 to 30/06/2020.

	All-cause deaths (n=576)					
Characteristic	Unadjusted HR (95% CI) p-value	Age & sex adjusted HR (95% CI) p-value	Multivariable HR (95% CI) p-value			
Sociodemographical						
Age (continuous yrs)	1.12 (1.12-1.13) < 0.001	1.13 (1.12-1.14) < 0.001	1.08 (1.07-1.09) <0.001			
Sex: women	0.82 (0.70-0.97) 0.020	0.58 (0.49-0.68) < 0.001	0.68 (0.56-0.81) < 0.001			
Nursing-home residence	24.37 (20.33-29.22) < 0.001	6.34 (5.18-7.76) < 0.001	1.63 (1.28-2.09) < 0.001			
Comorbidities						
Neurological disease	8.90 (7.28-10.89) < 0.001	2.55 (2.06-3.15) < 0.001	1.48 (1.18-1.85) 0.001			
Renal disease	5.13 (4.22-6.22) < 0.001	1.42 (1.17-1.74) 0.001	1.18 (0.95-1.46) 0.130			
Cancer	4.55 (3.80-5.44) < 0.001	2.64 (2.20-3.17) < 0.001	2.46 (2.03-2.98) < 0.001			
Rheumatic disease	1.59 (0.85-2.97) 0.146	1.42 (0.76-2.65) 0.276	0.89 (0.46-1.71) 0.717			
Respiratory disease	2.87 (2.36-3.49) < 0.001	1.75 (1.43-2.13) < 0.001	1.26 (0.96-1.66) 0.098			
Cardiac disease	4.14 (3.51-4.88) < 0.001	1.69 (1.43-2.00) < 0.001	1.29 (1.06-1.56) 0.009			
Atrial fibrillation	4.98 (4.06-6.11) < 0.001	1.50 (1.22-1.85) < 0.001	0.87 (0.63-1.19) 0.384			
Liver disease	2.12 (1.38-3.24) 0.001	2.68 (1.75-4.10) < 0.001	1.76 (1.14-2.73) 0.012			
Diabetes	2.31 (1.94-2.75) < 0.001	1.42 (1.19-1.69) < 0.001	1.07 (0.80-1.44) 0.652			
Hypertension	3.03 (2.53-3.62) < 0.001	1.08 (0.90-1.30) 0.399	1.19 (0.95-1.48) 0.125			
Obesity	0.94 (0.78-1.13) 0.513	0.92 (0.76-1.11) 0.274	0.89 (0.73-1.08) 0.219			
Smoking	0.60 (0.46-0.79) < 0.001	1.79 (1.35-2.38) < 0.001	1.30 (0.97-1.74) 0.078			
Alcoholism	1.31 (0.81-2.12) 0.273	2.14 (1.31-3.49) 0.002	1.42 (0.86-2.36) 0.173			
Chronic medications use			,			
Diuretics	5.95 (5.04-7.02) < 0.001	2.22 (1.86-2.64) < 0.001	1.55 (1.27-1.88) < 0.001			
Beta blockers	2.30 (1.90-2.78) < 0.001	1.36 (1.12-1.64) 0.002	1.11 (0.90-1.37) 0.351			
ACEIs	1.25 (1.03-1.51) 0.021	0.73 (0.60-0.88) 0.001	0.64 (0.52-0.79) < 0.001			
ARBs	0.99 (0.76-1.28) 0.927	0.59 (0.46-0.77) < 0.001	0.53 (0.40-0.71) < 0.001			
Calcium channel blockers	1.58 (1.23-2.02) < 0.001	0.83 (0.65-1.07) 0.151	0.81 (0.62-1.05) 0.114			
Statins	1.06 (0.87-1.29) 0.582	0.72 (0.59-0.88) 0.002	0.73 (0.57-0.92) 0.008			
Oral anticoagulants	3.59 (2.87-4.50) < 0.001	1.27 (1.01-1.59) 0.041	1.10 (0.77-1.57) 0.594			
Antiplatelet drugs	3.30 (2.76-3.95) < 0.001	1.37 (1.14-1.64) 0.001	1.20 (0.97-1.49) 0.096			
Insulin	2.93 (2.24-3.83) < 0.001	1.88 (1.44-2.46) < 0.001	1.15 (0.84-1.59) 0.376			
Oral antidiabetic drugs	1.76 (1.44-2.15) < 0.001	1.19 (0.97-1.45) 0.089	1.19 (0.87-1.62) 0.270			
Inhaled respiratory drugs	3.24 (2.66-3.95) < 0.001	1.77 (1.45-2.16) < 0.001	1.08 (0.82-1.44) 0.575			
Antineoplastic agents	1.37 (0.83-2.25) 0.213	1.40 (0.85-2.30) 0.187	0.63 (0.37-1.06) 0.082			
Systemic corticosteroids	6.81 (5.17-8.98) < 0.001	4.02 (3.05-5.30) < 0.001	3.49 (2.59-4.70) < 0.001			
NSADs	0.31 (0.16-0.57) < 0.001	0.52 (0.28-0.98) 0.043	0.65 (0.35-1.23) 0.189			
Antihistamines	0.45 (0.25-0.82) <0.001	0.52 (0.29-0.95) 0.034	0.58 (0.32-1.05) 0.073			
Proton-Pump Inhibitors	4.06 (3.45-4.78) < 0.001	1.81 (1.53-2.14) <0.001	1.25 (1.03-1.51) 0.026			
Benzodiazepines	2.06 (1.72-2.47) < 0.001	1.45 (1.20-1.74) <0.001	1.34 (1.11-1.61) 0.003			
Vaccination's history		(
Flu vaccine in prior autumn	4.04 (3.42-4.78) < 0.001	1.24 (1.04-1.48) 0.017	1.03 (0.84-1.27) 0.761			
PPV23	4.43 (3.72-5.29) <0.001	0.90 (0.75-1.09) 0.287	0.92 (0.72-1.18) 0.517			
PCV13	3.01 (2.00-4.53) < 0.001	1.81 (1.20-2.72) 0.005	1.13 (0.74-1.73) 0.577			
Tetanus	1.44 (1.20-1.72) <0.001	0.83 (0.69-0.99) 0.042	0.88 (0.70-1.10) 0.263			
Covid19-related status	(3.00 (0.00 0.00) 0.012	3.00 (0 0 1.10) 0.200			
Cas 4C: Covid19-nonrelated	Reference (-) < 0.001	Reference (-) < 0.001	Reference (-) < 0.001			
Covid19-negative	10.78 (8.86-13.12) <0.001	6.44 (5.28-7.87) < 0.001	4.24 (3.43-5.25) < 0.001			
Covid19-suspected	21.29 (10.01-45.30) < 0.001	35.89 (16.86-76.42) < 0.001	33.25 (15.53-71.20) <0.001			
Covid19-confirmed	181.20 (144.29-227.54) <0.001	74.31 (58.49-94.40) <0.001	45.97 (35.01-60.37) <0.001			

NOTE: HRs denotes Hazard ratios, and were calculated for those who had the condition as compared with those who had not the condition. In multivariable analysis the HRs were adjusted for age (continuous years), sex, residence, pre-existing comorbidities/underlying conditions, chronic medications use, vaccination's history and Covid19-related status across study period. Cls denote confidence intervals.

Table 6. Cox regression analyses assessing unadjusted, age & sex-adjusted and multivariable-adjusted risk of Covid19-related mortality in the total study cohort (N=79,083). Tarragona region (Southern Catalonia, Spain) from 01/03/2020 to 30/06/2020.

	COVID-19 deaths (n=124)				
Characteristic	Unadjusted HR (95% CI) p-value	Age & sex adjusted HR (95% CI) p-value	Multivariable HR (95% CI) p-value		
Sociodemographical					
Age (continuous yrs)	1.13 (1.12-1.15) <0.001	1.14 (1.12-1.16) <0.001	1.08 (1.06-1.10) < 0.001		
Sex: women	0.88 (0.62-1.25) 0.472	0.60 (0.42-0.85) 0.004	0.55 (0.37-0.81) 0.003		
Nursing-home residence	57.04 (40.11-81.11) < 0.001	17.05 (11.28-25.78) < 0.001	12.56 (8.07-19.54) < 0.001		
Comorbidities					
Neurological disease	10.30 (6.79-15.61) < 0.001	2.74 (1.77-4.23) < 0.001	1.35 (0.86-2.14) 0.198		
Renal disease	3.83 (2.44-6.03) < 0.001	0.99 (0.62-1.57) 0.952	0.98 (0.60-1.60) 0.943		
Cancer	2.51 (1.59-3.94) < 0.001	1.43 (0.90-2.25) 0.130	1.39 (0.86-2.23) 0.178		
Rheumatic disease	0.05 (0.01-92.92) 0.433	0.00 (-) 0.939	0.00 (-) 0.974		
Respiratory disease	2.77 (1.81-4.24) < 0.001	1.66 (1.08-2.55) 0.021	1.17 (0.66-2.08) 0.603		
Cardiac disease	3.79 (2.66-5.41) < 0.001	1.47 (1.02-2.11) 0.039	1.23 (0.81-1.85) 0.333		
Atrial fibrillation	4.58 (2.91-7.20) < 0.001	1.30 (0.82-2.07) 0.266	1.08 (0.54-2.16) 0.824		
Liver disease	1.32 (0.42-4.15) 0.635	1.71 (0.54-5.37) 0.361	1.17 (0.37-3.77) 0.790		
Diabetes	2.45 (1.68-3.56) < 0.001	1.50 (1.03-2.19) 0.033	0.85 (0.41-1.77) 0.670		
Hypertension	2.22 (1.54-3.21) < 0.001	0.74 (0.51-1.07) 0.110	0.79 (0.50-1.24) 0.297		
Obesity	0.84 (0.56-1.27) 0.420	0.84 (0.56-1.28) 0.418	0.89 (0.57-1.36) 0.580		
Smoking	0.51 (0.27-0.94) 0.031	1.66 (0.87-3.18) 0.126	1.20 (0.61-2.34) 0.600		
Alcoholism	1.07 (0.34-3.36) 0.911	1.92 (0.60-6.13) 0.272	1.07 (0.33-3.54) 0.910		
Chronic medications use			·		
Diuretics	5.49 (3.83-7.87) < 0.001	1.88 (1.29-2.74) 0.001	1.48 (0.97-2.25) 0.068		
Beta blockers	2.22 (1.47-3.37) < 0.001	1.30 (0.86-1.97) 0.214	1.24 (0.78-1.98) 0.355		
ACEIs	1.33 (0.89-1.99) 0.167	0.77 (0.51-1.15) 0.194	0.77 (0.49-1.22) 0.265		
ARBs	0.77 (0.42-1.43) 0.408	0.46 (0.25-0.85) 0.013	0.52 (0.26-1.01) 0.054		
Calcium channel blockers	1.90 (1.15-3.13) 0.012	0.99 (0.60-1.63) 0.970	1.14 (0.67-1.94) 0.633		
Statins	1.04 (0.67-1.59) 0.877	0.73 (0.47-1.12) 0.147	0.91 (0.54-1.52) 0.709		
Oral anticoagulants	3.08 (1.84-5.13) < 0.001	1.05 (0.63-1.76) 0.854	0.87 (0.40-1.92) 0.734		
Antiplatelet drugs	3.02 (2.04-4.46) < 0.001	1.21 (0.81-1.80) 0.356	1.08 (0.67-1.74) 0.750		
Insulin	2.69 (1.49-4.89) 0.001	1.72 (0.95-3.13) 0.073	1.01 (0.51-2.02) 0.970		
Oral antidiabetic drugs	2.35 (1.58-3.50) < 0.001	1.61 (1.08-2.40) 0.019	2.14 (1.03-4.43) 0.042		
Inhaled respiratory drugs	3.40 (2.23-5.18) < 0.001	1.81 (1.19-2.78) 0.006	1.45 (0.82-2.58) 0.207		
Antineoplastic agents	1.60 (0.59-4.33) 0.355	1.65 (0.61-4.47) 0.325	1.55 (0.55-4.39) 0.412		
Systemic corticosteroids	3.19 (1.41-7.25) 0.006	1.84 (0.81-4.19) 0.144	1.88 (0.80-4.41) 0.145		
NSADs	0.05 (0.01-1.42) 0.078	0.00 (-) 0.949	0.00 (-) 0.968		
Antihistamines	0.05 (0.01-2.38) 0.126	0.00 (-) 0.926	0.00 (-) 0.952		
Proton-Pump Inhibitors	2.82 (1.98-4.12) < 0.001	1.18 (0.83-1.69) 0.361	0.93 (0.61-1.41) 0.716		
Benzodiazepines	2.16 (1.47-3.17) < 0.001	1.48 (1.00-2.19) 0.052	1.40 (0.93-2.08) 0.104		
Vaccination's history					
Flu vaccine in prior autumn	6.14 (4.16-9.04) < 0.001	1.82 (1.21-2.73) 0.004	1.55 (0.98-2.47) 0.063		
PPV23	4.59 (3.13-6.72) < 0.001	0.86 (0.58-1.29) 0.468	1.00 (0.59-1.67) 0.990		
PCV13	2.30 (0.85-6.23) 0.101	1.37 (0.51-3.71) 0.537	1.15 (0.41-3.21) 0.794		
Tetanus	1.09 (0.75-1.58) 0.659	0.62 (0.43-0.90) 0.013	0.68 (0.43-1.08) 0.103		

NOTE: HRs denotes Hazard ratios, and were calculated for those who had the condition as compared with those who had not the condition. In multivariable analysis the HRs were adjusted for age (continuous years), sex, residence, pre-existing comorbidities/underlying conditions, chronic medications use and vaccination's history. Cls denote confidence intervals.

SUPPLEMENTARY TABLES

Supplementary Table S1. Incidence of all-cause mortality according to baseline demographical and clinical characteristics (comorbidities/medications) in community-dwelling individuals (N=77,669). Tarragona region (Southern Catalonia, Spain), 01/03/2020-30/06/2020.

	Study population	All·	-cause deaths (n=4	13)
Characteristic	(N=77669)	Univariate analysis	Time follow-up	Mortality rate
	n (%)	n (%) p-value	(persons-week)	MR* (95% CI)
Sociodemographical				, ,
Age: 50-64 yrs	42533 (54.8)	52 (12.6) < 0.001	731553	7.1 (5.3-9.4)
65-79 yrs	25712 (33.1)	134 (32.4)	442706	30.3 (25.6-35.9)
≥80 yrs	9424 (12.1)	227 (55.0)	160810	141.2 (124.5-160.1)
Sex Men	37143 (47.8)	237 (57.4) < 0.001	638226	37.1 (32.7-42.1)
Women	40526 (52.2)	176 (42.6)	696843	25.3 (21.8-29.3)
Comorbidities				
Neurological disease	1950 (2.5)	61 (14.8) < 0.001	33074	184.4 (142.0-239.7)
Renal disease	4240 (5.5)	98 (23.7) < 0.001	72114	135.9 (111.2-165.8)
Cancer	6461 (8.3)	141 (34.1) < 0.001	109968	128.2 (108.2-151.8)
Rheumatic disease	860 (1.1)	10 (2.4) 0.011	14699	68.0 (32.6-125.1)
Inflammatory bowel disease	520 (0.7)	7 (1.7) 0.010	8927	78.4 (31.4-161.5)
Respiratory disease	7074 (9.1)	104 (25.2) < 0.001	120762	86.1 (70.4-105.0)
Cardiac disease	12923 (16.6)	190 (46.0) < 0.001	221049	86.0 (74.1-99.8)
Atrial fibrillation	3560 (4.6)	80 (19.4) < 0.001	60657	131.9 (105.3-164.9)
Liver disease	1438 (1.9)	21 (5.1) < 0.001	24570	85.5 (52.9-130.8)
Diabetes	12925 (16.6)	130 (31.5) < 0.001	221837	58.6 (48.8-70.3)
Hypertension	33992 (43.8)	291 (70.5) < 0.001	583619	49.9 (44.5-55.9)
Hypercholesterolemia	26765 (34.5)	170 (41.2) 0.004	460087	36.9 (31.5-43.2)
Obesity	21343 (27.5)	122 (29.5) 0.347	366948	33.2 (27.7-39.8)
Smoking	12640 (16.3)	52 (12.6) 0.042	217755	23.9 (17.7-31.5)
Alcoholism	1756 (2.3)	15 (3.6) 0.060	30125	49.8 (27.9-82.2)
Chronic medications use				
Diuretics	8028 (10.3)	161 (39.0) < 0.001	136857	117.6 (100.4-137.7)
Beta blockers	9311 (12.0)	99 (24.0) < 0.001	159529	62.1 (50.8-75.8)
ACEIs	16030 (20.6)	104 (25.2) 0.022	275658	37.7 (30.8-46.0)
ARBs	8709 (11.2)	52 (12.6) 0.374	149802	34.7 (25.7-45.8)
Calcium channel blockers	6315 (8.1)	56 (13.6) < 0.001	108465	51.6 (39.7-67.1)
Statins	15910 (20.5)	107 (25.9) 0.006	273714	39.1 (32.0-47.7)
Oral anticoagulants	3741 (4.8)	66 (16.0) < 0.001	63865	103.3 (81.1-131.2)
Antiplatelet drugs	8809 (11.3)	124 (30.0) < 0.001	150896	82.2 (68.5-98.6)
Insulin	2904 (3.7)	41 (9.9) < 0.001	49699	82.5 (58.9-112.2)
Oral antidiabetic drugs	10352 (13.3)	90 (21.8) < 0.001	178039	50.6 (40.9-62.7)
Inhaled respiratory drugs	6095 (7.8)	103 (24.9) < 0.001	103830	99.2 (81.1-121.0)
Antineoplastic agents	1581 (2.0)	11 (2.7) 0.365	27209	40.4 (20.2-72.3)
Systemic corticosteroids	1216 (1.6)	52 (12.6) < 0.001	20457	254.2 (188.6-335.5)
NSADs	4305 (5.5)	9 (2.2) 0.003	73888	12.2 (5.6-23.2)
Antihistamines	3221 (4.1)	10 (2.4) 0.078	55545	18.0 (8.6-33.1)
Proton-Pump Inhibitors	17315 (22.3)	235 (56.9) < 0.001	296238	79.3 (69.9-89.9)
Benzodiazepines	12654 (16.3)	120 (29.1) < 0.001	216635	55.4 (46.1-66.5)
Vaccination's history				
Flu vaccine in prior autumn	21569 (27.8)	223 (54.0) < 0.001	370309	60.2 (52.3-69.3)
PPV23	25222 (32.5)	282 (68.3) < 0.001	432783	65.2 (58.2-73.1)
PCV13	1115 (1.4)	21 (5.1) < 0.001	18935	110.9 (68.6-169.7)
Tetanus	49817 (64.1)	318 (77.0) < 0.001	856072	37.1 (33.1-41.6)

NOTE: P-values in univariate analysis were calculated by chi-squared, or Fisher's test as appropriate, comparing percentages in the study population vs all-cause deaths cases; MR denotes mortality rates per 100.000 persons-week; CIs denotes confidence intervals for mortality rates and were calculated assuming a Poisson distribution for uncommon events.

Supplementary Table S2. Incidence of Covid19-related mortality according to baseline demographical and clinical characteristics (comorbidities/medications) in community-dwelling individuals (N=77,669). Tarragona region (Southern Catalonia, Spain), 01/03/2020-30/06/2020.

	Study population	covi	D-19 deaths (n=63)	
Characteristic	(N=77669)	Univariate analysis	Time follow-up	Mortality rate
	n (%)	n (%) p-value	(persons-week)	MR* (95% CI)
Sociodemographical		1	J	
Age: 50-64 yrs	42533 (54.8)	2 (3.2) < 0.001	731553	0.3 (0.1-1.1)
65-79 yrs	25712 (33.1)	30 (47.6)	442706	6.8 (4.6-9.7)
≥80 yrs	9424 (12.1)	31 (49.2)	160810	19.3 (13.0-27.6)
Sex Men	37143 (47.8)	35 (55.6) 0.219	638226	5.5 (3.8-7.6)
Women	40526 (52.2)	28 (44.4)	696843	4.0 (2.7-5.8)
Comorbidities				
Neurological disease	1950 (2.5)	8 (12.7) < 0.001	33074	24.2 (10.4-47.7)
Renal disease	4240 (5.5)	13 (20.6) < 0.001	72114	18.0 (9.6-30.8)
Cancer	6461 (8.3)	13 (20.6) < 0.001	109968	11.8 (6.3-20.2)
Rheumatic disease	860 (1.1)	0 (0.0) 0.401	14699	-
Inflammatory bowel disease	520 (0.7)	2 (3.2) 0.015	8927	22.4 (2.7-80.9)
Respiratory disease	7074 (9.1)	20 (31.7) < 0.001	120762	16.6 (10.1-25.6)
Cardiac disease	12923 (16.6)	29 (46.0) < 0.001	221049	13.1 (8.8-18.9)
Atrial fibrillation	3560 (4.6)	13 (20.6) < 0.001	60657	21.4 (11.4-36.6)
Liver disease	1438 (1.9)	3 (4.8) 0.086	24570	12.2 (2.5-35.6)
Diabetes	12925 (16.6)	20 (31.7) 0.001	221837	9.0 (5.5-13.9)
Hypertension	33992 (43.8)	42 (66.7) < 0.001	583619	7.2 (5.1-9.8)
Hypercholesterolemia	26765 (34.5)	24 (38.1) 0.544	460087	5.2 (3.3-7.7)
Obesity	21343 (27.5)	19 (30.2) 0.634	366948	5.2 (3.1-8.1)
Smoking	12640 (16.3)	5 (7.9) 0.073	217755	2.3 (0.7-5.4)
Alcoholism	1756 (2.3)	2 (3.2) 0.625	30125	6.6 (0.8-23.8)
Chronic medications use	1700 (2.0)	2 (0.2) 0.020	00120	0.0 (0.0 20.0)
Diuretics	8028 (10.3)	27 (42.9) < 0.001	136857	19.7 (13.0-28.8)
Beta blockers	9311 (12.0)	18 (28.6) < 0.001	159529	11.3 (6.7-17.9)
ACEIS	16030 (20.6)	15 (23.8) 0.534	275658	5.4 (3.0-8.9)
ARBs	8709 (11.2)	9 (14.3) 0.439	149802	6.0 (2.7-11.4)
Calcium channel blockers	6315 (8.1)	10 (15.9) 0.024	108465	9.2 (4.4-16.9)
Statins	15910 (20.5)	17 (27.0) 0.201	273714	6.2 (3.6-9.9)
Oral anticoagulants	3741 (4.8)	13 (20.6) < 0.001	63865	20.4 (10.9-34.9)
Antiplatelet drugs	8809 (11.3)	16 (25.4) < 0.001	150896	10.6 (6.1-17.2)
Insulin	2904 (3.7)	5 (7.9) 0.079	49699	10.0 (0.1-17.2)
Oral antidiabetic drugs	10352 (13.3)	17 (27.0) 0.001	178039	9.5 (5.5-15.2)
Inhaled respiratory drugs	6095 (7.8)	21 (33.3) <0.001	103830	20.2 (12.5-30.9)
Antineoplastic agents	1581 (2.0)	1 (1.6) 0.801	27209	3.7 (0.1-20.6)
Systemic corticosteroids	1216 (1.6)	6 (9.5) < 0.001	20457	29.3 (10.8-63.9)
NSADs	4305 (5.5)	0 (0.0) 0.054	73888	, ,
Antihistamines	3221 (4.1)	0 (0.0) 0.034	55545	-
Proton-Pump Inhibitors	` ,	` ,	296238	11.1(7.7-15.4)
Benzodiazepines	17315 (22.3) 12654 (16.3)	33 (52.4) < 0.001		· · · · · · · · · · · · · · · · · · ·
Vaccination's history	12004 (10.3)	20 (31.7) 0.001	216635	9.2 (5.6-14.2)
	21560 (27.9)	25 (55 G) ±0 004	270200	0.5 (6.6.12.0)
Flu vaccine in prior autumn	21569 (27.8)	35 (55.6) < 0.001	370309	9.5 (6.6-13.2)
PPV23	25222 (32.5)	45 (71.4) < 0.001	432783	10.4 (7.6-13.9)
PCV13	1115 (1.4)	3 (4.8) 0.026	18935	15.8 (3.3-46.1)
Tetanus	49817 (64.1)	46 (73.0) 0.142	856072	5.4 (3.9-7.2)

NOTE: P-values in univariate analysis were calculated by chi-squared, or Fisher's test as appropriate, comparing percentages in the study population vs Covid19-related cases; MR denotes mortality rates per 100.000 persons-week; CIs denotes confidence intervals for mortality rates and were calculated assuming a Poisson distribution for uncommon events

Supplementary Table S3. Cox regression analyses assessing unadjusted, age & sex-adjusted and multivariable-adjusted risk of all-cause mortality in community-dwelling individuals (N=77,669). Tarragona region (Southern Catalonia, Spain) from 01/03/2020 to 30/06/2020.

	All-cause deaths (n=413)					
Characteristic	Unadjusted	Age & sex adjusted	Multivariable			
	HR (95% CI) p-value	HR (95% CI) p-value	HR (95% CI) p-value			
Sociodemographical						
Age (continuous yrs)	1.11 (1.10-1.12) <0.001	1.11 (1.10-1.12) <0.001	1.09 (1.08-1.10) <0.001			
Sex: women	0.68 (0.56-0.83) < 0.001	0.52 (0.43-0.63) < 0.001	0.63 (0.51-0.78) < 0.001			
Comorbidities						
Neurological disease	6.81 (5.19-8.94) < 0.001	2.25 (1.70-2.98) < 0.001	1.67 (1.25-2.23) 0.001			
Renal disease	5.44 (4.34-6.83) < 0.001	1.66 (1.31-2.10) <0.001	1.25 (0.97-1.61) 0.085			
Cancer	5.77 (4.71-7.07) <0.001	3.35 (2.72-4.12) < 0.001	2.87 (2.32-3.55) < 0.001			
Rheumatic disease	2.23 (1.19-4.17) 0.012	2.00 (1.07-3.74) 0.031	1.12 (0.57-2.17) 0.747			
Respiratory disease	3.38 (2.71-4.23) < 0.001	2.09 (1.67-2.62) < 0.001	1.23 (0.87-1.74) 0.246			
Cardiac disease	4.29 (3.54-5.21) < 0.001	1.89 (1.55-2.32) <0.001	1.35 (1.07-1.70) 0.011			
Atrial fibrillation	5.05 (3.95-6.44) < 0.001	1.63 (1.27-2.11) < 0.001	1.31 (0.87-1.97) 0.202			
Liver disease	2.86 (1.84-4.43) < 0.001	3.56 (2.30-5.53) < 0.001	2.43 (1.55-3.81) < 0.001			
Diabetes	2.31 (1.87-2.84) < 0.001	1.41 (1.15-1.74) 0.001	1.22 (0.84-1.75) 0.296			
Hypertension	3.07 (2.49-3.79) < 0.001	1.21 (0.97-1.51) 0.087	1.29 (0.99-1.69) 0.063			
Obesity	1.11 (0.90-1.37) 0.350	1.05 (0.85-1.29) 0.683	0.98 (0.78-1.22) 0.834			
Smoking	0.74 (0.55-0.99) 0.042	1.83 (1.35-2.49) < 0.001	1.59 (1.16-2.19) 0.004			
Alcoholism	1.63 (0.98-2.73) 0.062	2.31 (1.37-3.90) 0.002	1.66 (0.97-2.86) 0.065			
Chronic medications use						
Diuretics	5.59 (4.59-6.81) < 0.001	2.36 (1.91-2.91) < 0.001	1.54 (1.21-1.95) <0.001			
Beta blockers	2.32 (1.85-2.91) < 0.001	1.39 (1.10-1.74) 0.005	0.99 (0.77-1.27) 0.947			
ACEIs	1.29 (1.04-1.62) 0.023	0.76 (0.61-0.95) 0.015	0.59 (0.46-0.75) < 0.001			
ARBs	1.14 (0.85-1.52) 0.377	0.67 (0.50-0.90) 0.008	0.47 (0.34-0.65) < 0.001			
Calcium channel blockers	1.77 (1.34-2.35) <0.001	0.95 (0.71-1.26) 0.698	0.85 (0.63-1.14) 0.262			
Statins	1.36 (1.09-1.69) 0.007	0.86 (0.69-1.07) 0.185	0.70 (0.54-0.91) 0.006			
Oral anticoagulants	3.79 (2.91-4.93) < 0.001	1.37 (1.05-1.80) 0.020	0.87 (0.55-1.37) 0.537			
Antiplatelet drugs	3.37 (2.73-4.16) < 0.001	1.45 (1.17-1.80) 0.001	1.14 (0.88-1.48) 0.322			
Insulin	2.85 (2.07-3.94) < 0.001	1.86 (1.35-2.57) < 0.001	1.16 (0.79-1.69) 0.450			
Oral antidiabetic drugs	1.81 (1.43-2.29) <0.001	1.18 (0.93-1.49) 0.166	0.98 (0.67-1.42) 0.895			
Inhaled respiratory drugs	3.94 (3.15-4.92) < 0.001	2.22 (1.77-2.78) < 0.001	1.31 (0.92-1.86) 0.134			
Antineoplastic agents	1.32 (0.72-2.40) 0.370	1.32 (0.72-2.40) 0.369	0.60 (0.32-1.12) 0.106			
Systemic corticosteroids	9.24 (6.91-12.35) < 0.001	5.59 (4.17-7.48) < 0.001	3.60 (2.61-4.96) < 0.001			
NSADs	0.38 (0.20-0.74) 0.004	0.59 (0.30-1.14) 0.118	0.58 (0.30-1.13) 0.108			
Antihistamines	0.57 (0.31-1.07) 0.081	0.64 (0.34-1.19) 0.159	0.52 (0.27-0.97) 0.040			
Proton-Pump Inhibitors	4.63 (3.81-5.62) < 0.001	2.25 (1.84-2.76) < 0.001	1.60 (1.26-2.01) < 0.001			
Benzodiazepines	2.11 (1.71-2.61) <0.001	1.59 (1.28-1.98) <0.001	1.34 (1.07-1.67) 0.011			
Vaccination's history						
Flu vaccine in prior autumn	3.06 (2.52-3.71) < 0.001	1.03 (0.84-1.27) 0.779	0.88 (0.70-1.13) 0.317			
PPV23	4.49 (3.65-5.52) < 0.001	1.05 (0.83-1.32) 0.688	0.90 (0.67-1.21) 0.477			
PCV13	3.72 (2.40-5.77) < 0.001	2.21 (1.42-3.43) < 0.001	1.14 (0.72-1.82) 0.584			
Tetanus	1.87 (1.49-2.36) <0.001	1.06 (0.84-1.34) 0.618	0.94 (0.72-1.23) 0.655			

NOTE: HRs denotes Hazard ratios, and were calculated for those who had the condition as compared with those who had not the condition. In multivariable analysis the HRs were adjusted for age (continuous years), sex, pre-existing comorbidities/underlying conditions, chronic medications use and vaccination's history. Cls denote confidence intervals.

Supplementary Table S4. Cox regression analyses assessing unadjusted, age & sex-adjusted and multivariable-adjusted risk of Covid19-related mortality in community-dwelling individuals (N=77,669). Tarragona region (Southern Catalonia, Spain) from 01/03/2020 to 30/06/2020.

	COVID-19 deaths (n=63)				
Characteristic	Unadjusted HR (95% CI) p-value	Age & sex adjusted HR (95% CI) p-value	Multivariable HR (95% CI) p-value		
Sociodemographical	1111 (00 /0 0.) p 10.00	1111 (00% 01) p 141140	ти (осло слур талас		
Age (continuous yrs)	1.11 (1.09-1.13) < 0.001	1.11 (1.09-1.14) < 0.001	1.08 (1.05-1.12) < 0.001		
Sex: women	0.73 (0.45-1.21) 0.221	0.56 (0.34-0.92) 0.023	0.63 (0.36-1.09) 0.099		
Comorbidities		,	,		
Neurological disease	5.69 (2.71-11.94) < 0.001	1.86 (0.87-3.99) 0.111	1.45 (0.66-3.20) 0.354		
Renal disease	4.53 (2.46-8.34) < 0.001	1.36 (0.72-2.57) 0.343	1.04 (0.53-2.03) 0.914		
Cancer	2.88 (1.57-5.31) 0.001	1.65 (0.89-3.07) 0.112	1.43 (0.76-2.68) 0.271		
Rheumatic disease	0.05 (0.00-1914.01) 0.576	0.00 (-) 0.955	0.00 (-) 0.977		
Respiratory disease	4.67 (2.75-7.93) < 0.001	2.94 (1.72-5.04) < 0.001	1.46 (0.63-3.39) 0.379		
Cardiac disease	4.29 (2.61-7.04) < 0.001	1.90 (1.14-3.19) 0.014	1.41 (0.78-2.56) 0.255		
Atrial fibrillation	5.45 (2.96-10.03) < 0.001	1.80 (0.95-3.38) 0.071	0.78 (0.25-2.45) 0.673		
Liver disease	2.66 (0.84-8.49) 0.098	3.31 (1.04-10.59) 0.043	2.34 (0.71-7.69) 0.161		
Diabetes	2.33 (1.37-3.97) 0.002	1.44 (0.84-2.45) 0.181	0.78 (0.25-2.43) 0.664		
Hypertension	2.57 (1.52-4.45) < 0.001	1.00 (0.58-1.73) 0.997	0.97 (0.50-1.91) 0.936		
Obesity	1.14 (0.67-1.95) 0.635	1.07 (0.62-1.84) 0.808	0.93 (0.52-1.64) 0.796		
Smoking	0.44 (0.18-1.10) 0.080	1.06 (0.41-2.72) 0.913	0.89 (0.34-2.35) 0.807		
Alcoholism	1.42 (0.35-5.80) 0.626	2.05 (0.49-8.56) 0.325	1.68 (0.39-7.31) 0.488		
Chronic medications use					
Diuretics	6.54 (3.97-10.77) < 0.001	2.80 (1.65-4.78) < 0.001	1.89 (1.03-3.46) 0.041		
Beta blockers	2.94 (1.70-5.08) < 0.001	1.76 (1.02-3.05) 0.043	1.35 (0.73-2.49) 0.341		
ACEIs	1.20 (0.67-2.15) 0.535	0.71 (0.40-1.27) 0.246	0.59 (0.30-1.14) 0.114		
ARBs	1.32 (0.65-2.67) 0.441	0.78 (0.39-1.58) 0.492	0.53 (0.24-1.17) 0.114		
Calcium channel blockers	2.13 (1.08-4.19) 0.028	1.14 (0.58-2.26) 0.699	1.12 (0.55-2.29) 0.753		
Statins	1.44 (0.82-2.50) 0.203	0.92 (0.53-1.60) 0.766	0.74 (0.38-1.42) 0.364		
Oral anticoagulants	5.17 (2.81-9.51) < 0.001	1.93 (1.03-3.60) 0.040	1.38 (0.42-4.46) 0.595		
Antiplatelet drugs	2.67 (1.51-4.70) 0.001	1.15 (0.64-2.05) 0.646	0.90 (0.45-1.81) 0.776		
Insulin	2.23 (0.89-5.56) 0.086	1.46 (0.59-3.64) 0.418	0.92 (0.33-2.59) 0.879		
Oral antidiabetic drugs	2.40 (1.38-4.19) 0.002	1.58 (0.90-2.76) 0.109	2.00 (0.64-6.21) 0.233		
Inhaled respiratory drugs	5.91 (3.50-9.98) <0.001	3.41 (2.00-5.82) < 0.001	2.03 (0.87-4.73) 0.102		
Antineoplastic agents	0.78 (0.11-5.60) 0.801	0.77 (0.11-5.57) 0.798	0.58 (0.08-4.37) 0.592		
Systemic corticosteroids	6.69 (2.89-15.52) < 0.001	4.05 (1.74-9.42) 0.001	3.10 (1.27-7.59) 0.013		
NSADs	0.046 (0.00-5.48) 0.206	0.00 (-) 0.961	0.00 (-) 0.969		
Antihistamines	0.047 (0.00-11.44) 0.275	0.00 (-) 0.964	0.00 (-) 0.968		
Proton-Pump Inhibitors	3.85 (2.35-6.31) < 0.001	1.85 (1.11-3.08) 0.019	1.29 (0.71-2.32) 0.404		
Benzodiazepines	2.40 (1.41-4.07) 0.001	1.79 (1.04-3.08) 0.037	1.60 (0.92-2.79) 0.098		
Vaccination's history					
Flu vaccine in prior autumn	3.26 (1.98-5.35) < 0.001	1.12 (0.66-1.89) 0.686	0.90 (0.49-1.64) 0.721		
PPV23	5.21 (3.01-8.99) < 0.001	1.28 (0.69-2.36) 0.435	1.37 (0.62-3.04) 0.443		
PCV13	3.46 (1.09-11.03) 0.036	2.07 (0.65-6.61) 0.221	1.11 (0.33-3.76) 0.862		
Tetanus	1.51 (0.87-2.64) 0.144	0.86 (0.49-1.51) 0.595	0.63 (0.32-1.25) 0.186		

NOTE: HRs denotes Hazard ratios, and were calculated for those who had the condition as compared with those who had not the condition. In multivariable analysis the HRs were adjusted for age (continuous years), sex, pre-existing comorbidities/underlying conditions, chronic medications use and vaccination's history. Cls denote confidence intervals.

Supplementary Table S5. Incidence of all-cause mortality according to baseline demographical and clinical characteristics (comorbidities/medications) in nursing-home residents (N=1,414). Tarragona region (Southern Catalonia, Spain), 01/03/2020-30/06/2020.

	Study population			
Characteristic	(N=1414)	Univariate analysis	Time follow-up	Mortality rate
	n (%)	n (%) p value	(persons-week)	MR* (95% CI)
Sociodemographical	1		1	1
Age: 50-64 yrs	151 (10.7)	2 (1.2) < 0.001	2570	77.8 (9.4-280.9)
65-79 yrs	301 (21.3)	15 (9.2)	4768	314.6 (176.2-519.1)
≥80 yrs	962 (68.0)	146 (89.6)	13951	1046.5 (883.1-1239.1)
Sex: Men	483 (34.2)	65 (39.9) 0.102	7245	897.2 (704.3-1139.4)
Women	931 (65.8)	98 (60.1)	14045	697.8 (570.8-851.3)
Comorbidities				
Neurological disease	367 (26.0)	58 (35.6) 0.003	5270	1100.6 (847.5-1430.8)
Renal disease	236 (16.7)	36 (22.1) 0.050	3515	1024.2 (713.9-1423.6)
Cancer	169 (12.0)	27 (16.6) 0.054	2514	1074.0 (707.8-1568.0)
Rheumatic disease	12 (0.8)	0 (0.0) 0.209	199	-
Inflammatory bowel disease	12 (0.8)	1 (0.6) 0.728	170	588.2 (14.9-3276.3)
Respiratory disease	198 (14.0)	25 (15.3) 0.602	3032	824.5 (533.5-1220.3)
Cardiac disease	512 (36.2)	73 (44.8) 0.015	7666	952.3 (747.6-1209.4)
Atrial fibrillation	226 (16.0)	34 (20.9) 0.071	3305	1028.7 (717.0-1429.9)
Liver disease	27 (1.9)	1 (0.6) 0.199	428	233.6 (5.9-1301.2)
Diabetes	392 (27.7)	53 (32.5) 0.146	5803	913.3 (677.7-1205.6)
Hypertension	953 (67.4)	115 (70.6) 0.361	14270	805.9 (671.3-967.1)
Hypercholesterolemia	549 (38.8)	58 (35.6) 0.366	8449	686.5 (528.6-892.5)
Obesity	335 (23.7)	29 (17.8) 0.060	5138	564.4 (378.1-812.7)
Smoking	110 (7.8)	8 (4.9) 0.146	1763	453.8 (195.6-894.0)
Alcoholism	40 (2.8)	2 (1.2) 0.190	649	308.2 (37.3-1112.6)
Chronic medications use	,	,	1	,
Diuretics	453 (32.0)	77 (47.2) < 0.001	6501	1184.4 (945.2-1480.5)
Beta blockers	260 (18.4)	39 (23.9) 0.052	3921	994.6 (710.1-1352.7)
ACEIs	389 (27.5)	38 (23.3) 0.202	5856	648.9 (452.3-902.0)
ARBs	160 (11.3)	12 (7.4) 0.090	2574	466.2 (241.0-815.9)
Calcium channel blockers	175 (12.4)	15 (9.2) 0.191	2642	567.8 (318.0-936.9)
Statins	224 (15.8)	16 (9.8) 0.025	3523	454.2 (259.8-735.8)
Oral anticoagulants	171 (12.1)	24 (14.7) 0.273	2559	937.9 (601.2-1397.5)
Antiplatelet drugs	345 (24.4)	49 (30.1) 0.074	5061	968.2 (718.4-1278.0)
Insulin	138 (9.8)	19 (11.7) 0.386	2042	930.5 (560.2-1451.6)
Oral antidiabetic drugs	233 (16.5)	33 (20.2) 0.168	3413	966.9 (673.9-1344.0)
Inhaled respiratory drugs	198 (14.0)	22 (13.5) 0.843	3027	726.8 (455.7-1097.5)
Antineoplastic agents	33 (2.3)	5 (3.1) 0.509	482	1037.3 (336.1-2416.9)
Systemic corticosteroids	36 (2.5)	4 (2.5) 0.937	573	698.1 (189.9-1787.1)
NSADs	16 (1.1)	1 (0.6) 0.506	264	378.8 (9.6-2109.9)
Antihistamines	43 (3.0)	1 (0.6) 0.055	698	143.3 (3.6-798.2)
Proton-Pump Inhibitors	616 (43.6)	77 (47.2) 0.314	9327	825.6 (658.8-1032.0)
Benzodiazepines	392 (27.7)	46 (28.2) 0.880	5902	779.4 (568.2-1044.4)
Vaccination's history	, ,	, ,	<u> </u>	
Flu vaccine in prior autumn	1037 (73.3)	132 (81.0) 0.019	15359	859.4 (725.3-1017.5)
PPV23	961 (68.0)	113 (69.3) 0.692	14487	780.0 (649.7-936.0)
PCV13	24 (1.7)	3 (1.8) 0.880	337	890.2 (183.4-2599.4)
Tetanus	982 (69.4)	97 (59.5) 0.003	15132	641.0 (524.3-782.0)

NOTE: P-values in univariate analysis were calculated by chi-squared, or Fisher's test as appropriate, comparing percentages in the study population vs all-cause deaths cases; MR denotes mortality rates per 100.000 persons-week; CIs denotes confidence intervals for mortality rates and were calculated assuming a Poisson distribution for uncommon events.

Supplementary Table S6. Incidence of Covid19-related mortality according to baseline demographical and clinical characteristics (comorbidities/medications) in nursing-home residents (N=1,414). Tarragona region (Southern Catalonia, Spain), 01/03/2020-30/06/2020.

	Study population	y population COVID-19 deaths (n=61)		
Characteristic	(N=1414)	Univariate analysis	Time follow-up	Mortality rate
	n (%)	n (%) p value	(persons-week)	MR* (95% CI)
Sociodemographical	1	<u>I</u>	1	
Age: 50-64 yrs	151 (10.7)	1 (1.6) 0.001	2570	38.9 (1.0-216.7)
65-79 yrs	301 (21.3)	`5 (8.2)	4768	104.9 (34.0-244.4)
≥80 yrs	962 (68.0)	55 (90.2)	13951	394.2 (303.5-512.5)
Sex: Men	483 (34.2)	28 (45.9) 0.048	7245	386.5 (257.0-560.4)
Women	931 (65.8)	33 (54.1)	14045	235.0 (163.8-326.7)
Comorbidities				
Neurological disease	367 (26.0)	21 (34.4) 0.123	5270	398.5 (246.7-609.7)
Renal disease	236 (16.7)	10 (16.4) 0.949	3515	284.5 (136.6-523.5)
Cancer	169 (12.0)	10 (16.4) 0.274	2514	397.8 (190.9-732.0)
Rheumatic disease	12 (0.8)	0 (0.0) 0.460	199	-
Inflammatory bowel disease	12 (0.8)	0 (0.0) 0.460	170	-
Respiratory disease	198 (14.0)	7 (11.5) 0.561	3032	230.9 (92.6-475.7)
Cardiac disease	512 (36.2)	25 (41.0) 0.428	7666	326.1 (211.0-482.6)
Atrial fibrillation	226 (16.0)	10 (16.4) 0.929	3305	302.6 (145.2-556.8)
Liver disease	27 (1.9)	0 (0.0) 0.265	428	-
Diabetes	392 (27.7)	21 (34.4) 0.232	5803	361.9 (224.0-553.7)
Hypertension	953 (67.4)	37 (60.7) 0.251	14270	259.3 (180.7-360.4)
Hypercholesterolemia	549 (38.8)	24 (39.3) 0.932	8449	284.1 (182.1-423.3)
Obesity	335 (23.7)	11 (18.0) 0.288	5138	214.1 (106.8-383.2)
Smoking	110 (7.8)	6 (9.8) 0.540	1763	340.3 (124.9-741.9)
Alcoholism	40 (2.8)	1 (1.6) 0.567	649	154.1 (3.9-858.3)
Chronic medications use	- (- /	(-,		
Diuretics	453 (32.0)	22 (36.1) 0.491	6501	338.4 (212.2-511.0)
Beta blockers	260 (18.4)	11 (18.0) 0.942	3921	280.5 (140.0-502.1)
ACEIs	389 (27.5)	17 (27.9) 0.949	5856	290.3 (169.2-464.5)
ARBs	160 (11.3)	2 (3.3) 0.043	2574	77.7 (9.4-280.5)
Calcium channel blockers	175 (12.4)	8 (13.1) 0.858	2642	302.8 (130.5-596.5)
Statins	224 (15.8)	9 (14.8) 0.812	3523	255.5 (117.0-485.5)
Oral anticoagulants	171 (12.1)	4 (6.6) 0.175	2559	156.3 (42.5-400.1)
Antiplatelet drugs	345 (24.4)	19 (31.1) 0.210	5061	375.4 (226.0-585.6)
Insulin	138 (9.8)	7 (11.5) 0.644	2042	342.8 (137.5-706.2)
Oral antidiabetic drugs	233 (16.5)	16 (26.2) 0.036	3413	468.8 (268.2-759.5)
Inhaled respiratory drugs	198 (14.0)	7 (11.5) 0.561	3027	231.3 (92.8-476.5)
Antineoplastic agents	33 (2.3)	3 (4.9) 0.172	482	622.4 (128.2-1817.4)
Systemic corticosteroids	36 (2.5)	0 (0.0) 0.197	573	-
NSADs	16 (1.1)	0 (0.0) 0.393	264	-
Antihistamines	43 (3.0)	0 (0.0) 0.157	698	-
Proton-Pump Inhibitors	616 (43.6)	23 (37.7) 0.345	9327	246.6 (156.3-369.9)
Benzodiazepines	392 (27.7)	17 (27.9) 0.979	5902	288.0 (167.9-460.8)
Vaccination's history	JJ (2)	(=) 0.0.0		
Flu vaccine in prior autumn	1037 (73.3)	53 (86.9) 0.014	15359	345.1 (256.1-455.5)
PPV23	961 (68.0)	41 (67.2) 0.898	14487	283.0 (202.1-384.9)
PCV13	24 (1.7)	1 (1.6) 0.971	337	296.7 (7.5-1652.6)
Tetanus	982 (69.4)	36 (59.0) 0.071	15132	237.9 (165.8-330.7)

NOTE: P-values in univariate analysis were calculated by chi-squared, or Fisher's test as appropriate, comparing percentages in the study population vs Covid19-related cases; MR denotes mortality rates per 100.000 persons-week; Cls denotes confidence intervals for mortality rates and were calculated assuming a Poisson distribution for uncommon events.

Supplementary Table S7. Cox regression analyses assessing unadjusted, age & sex-adjusted and multivariable-adjusted risk of all-cause mortality in nursing-home residents (N=1,414). Tarragona region (Southern Catalonia, Spain) from 01/03/2020 to 30/06/2020.

	All-cause deaths (n=163)						
Characteristic	Unadjusted HR (95% CI) p-value	Age & sex adjusted HR (95% CI) p-value	Multivariable HR (95% CI) p-value				
Sociodemographical							
Age (continuous yrs)	1.06 (1.04-1.08) < 0.001	1.07 (1.05-1.09) < 0.001	1.05 (1.03-1.08) <0.001				
Sex: women	0.77 (0.57-1.06) 0.110	0.56 (0.40-0.77) < 0.001	0.55 (0.39-0.78) 0.001				
Comorbidities							
Neurological disease	1.64 (1.19-2.26) 0.002	1.39 (1.01-1.93) 0.047	1.33 (0.95-1.87) 0.095				
Renal disease	1.45 (1.00-2.09) 0.051	1.10 (0.76-1.60) 0.622	1.19 (0.80-1.77) 0.389				
Cancer	1.49 (0.98-2.24) 0.061	1.33 (0.88-2.03) 0.176	1.38 (0.89-2.16) 0.151				
Rheumatic disease	0.05 (0.01-66.40) 0.413	0.00 (-) 0.956	NA (-) 0.951				
Respiratory disease	1.10 (0.72-1.68) 0.670	0.98 (0.64-1.51) 0.937	0.95 (0.56-1.60) 0.845				
Cardiac disease	1.45 (1.06-1.97) 0.019	1.22 (0.90-1.66) 0.208	1.09 (0.77-1.54) 0.638				
Atrial fibrillation	1.44 (0.98-2.09) 0.061	1.11 (0.76-1.63) 0.582	0.88 (0.52-1.52) 0.654				
Liver disease	0.31 (0.04-2.20) 0.240	0.34 (0.05-2.41) 0.278	0.24 (0.03-1.76) 0.161				
Diabetes	1.28 (0.92-1.78) 0.140	1.28 (0.92-1.78) 0.140	1.12 (0.66-1.90) 0.683				
Hypertension	1.17 (0.84-1.64) 0.358	0.94 (0.67-1.32) 0.703	0.99 (0.67-1.47) 0.976				
Obesity	0.68 (0.46-1.02) 0.063	0.80 (0.54-1.20) 0.285	0.79 (0.52-1.21) 0.276				
Smoking	0.58 (0.29-1.18) 0.135	1.00 (0.48-2.11) 0.998	0.96 (0.44-2.10) 0.926				
Alcoholism	0.40 (0.10-1.62) 0.199	0.54 (0.13-2.19) 0.385	0.43 (0.10-1.83) 0.254				
Chronic medications use							
Diuretics	2.01 (1.48-2.73) < 0.001	1.63 (1.19-2.22) 0.002	1.68 (1.19) 2.38) 0.003				
Beta blockers	1.41 (0.98-2.02) 0.061	1.34 (0.93-1.92) 0.112	1.23 (0.82-1.85) 0.315				
ACEIs	0.80 (0.56-1.15) 0.223	0.78 (0.54-1.12) 0.177	0.72 (0.48-1.07) 0.099				
ARBs	0.59 (0.33-1.06) 0.075	0.63 (0.35-1.14) 0.124	0.58 (0.31-1.09) 0.091				
Calcium channel blockers	0.71 (0.42-1.21) 0.210	0.71 (0.42-1.20) 0.198	0.75 (0.43-1.31) 0.310				
Statins	0.56 (0.33-0.93) 0.026	0.76 (0.45-1.28) 0.299	0.67 (0.38-1.19) 0.175				
Oral anticoagulants	1.27 (0.82-1.96) 0.284	1.12 (0.72-1.73) 0.616	1.13 (0.60-2.13) 0.713				
Antiplatelet drugs	1.37 (0.98-1.92) 0.065	1.22 (0.87-1.71) 0.245	1.33 (0.88-2.02) 0.173				
Insulin	1.24 (0.77-2.00) 0.380	1.29 (0.80-2.09) 0.294	0.78 (0.54-1.76) 0.936				
Oral antidiabetic drugs	1.32 (0.90-1.93) 0.154	1.43 (0.97-2.10) 0.072	1.52 (0.86-2.67) 0.146				
Inhaled respiratory drugs	0.95 (0.60-1.49) 0.813	0.85 (0.54-1.34) 0.484	0.81 (0.47-1.39) 0.438				
Antineoplastic agents	1.34 (0.55-3.27) 0.515	1.54 (0.63-3.77) 0.339	1.65 (0.62-4.39) 0.318				
Systemic corticosteroids	0.91 (0.34-2.46) 0.856	0.89 (0.33-2.40) 0.814	0.97 (0.35-2.69) 0.948				
NSADs	0.51 (0.07-3.67) 0.506	1.21 (0.17-8.73) 0.849	1.42 (0.19-10.42) 0.731				
Antihistamines	0.19 (0.03-1.33) 0.093	0.25 (0.03-1.76) 0.162	0.26 (0.04-1.84) 0.176				
Proton-Pump Inhibitors	1.15 (0.85-1.57) 0.370	1.01 (0.74-1.37) 0.954	0.86 (0.60-1.25) 0.435				
Benzodiazepines	1.02 (0.73-1.44) 0.900	1.08 (0.77-1.53) 0.647	1.07 (0.75-1.54) 0.705				
Vaccination's history							
Flu vaccine in prior autumn	1.63 (1.10-2.41) 0.014	1.34 (0.91-1.99) 0.141	1.30 (0.86-1.95) 0.216				
PPV23	1.06 (0.76-1.48) 0.732	0.79 (0.56-1.10) 0.157	0.90 (0.59-1.36) 0.616				
PCV13	1.13 (0.36-3.55) 0.832	0.96 (0.31-3.03) 0.949	0.82 (0.25-2.68) 0.743				
Tetanus	0.61 (0.45-0.83) 0.002	0.68 (0.49-0.93) 0.016	0.65 (0.44-0.97) 0.036				

NOTE: HRs denotes Hazard ratios, and were calculated for those who had the condition as compared with those who had not the condition. In multivariable analysis the HRs were adjusted for age (continuous years), sex, pre-existing comorbidities/underlying conditions, chronic medications use and vaccination's history. Cls denote confidence intervals.

Supplementary Table S8. Cox regression analyses assessing unadjusted, age & sex-adjusted and multivariable-adjusted risk of Covid19-related mortality in nursing-home residents (N=1,414). Tarragona region (Southern Catalonia, Spain) from 01/03/2020 to 30/06/2020.

COVID-19 deaths (n=61)					
Characteristic	Unadjusted	Age & sex adjusted	Multivariable		
	HR (95% CI) p-value	HR (95% CI) p-value	HR (95% CI) p-value		
Sociodemographical					
Age (continuous yrs)	1.05 (1.02-1.08) 0.001	1.06 (1.03-1.09) < 0.001	1.06 (1.03-1.10) <0.001		
Sex: women	0.60 (0.36-1.00) 0.049	0.45 (0.27-0.76) 0.003	0.46 (0.26-0.83) 0.009		
Comorbidities					
Neurological disease	1.53 (0.90-2.60) 0.114	1.37 (0.80-2.35) 0.248	1.19 (0.68-2.08) 0.545		
Renal disease	1.01 (0.51-1.99) 0.978	0.76 (0.39-1.51) 0.437	0.87 (0.42-1.80) 0.714		
Cancer	1.47 (0.75-2.90) 0.265	1.27 (0.64-2.51) 0.499	1.17 (0.56-2.46) 0.677		
Rheumatic disease	0.05 (0.01-6912.09) 0.618	0.00 (-) 0.973	0.00 (-) 0.987		
Respiratory disease	0.79 (0.36-1.74) 0.556	0.68 (0.31-1.50) 0.342	0.67 (0.26-1.71) 0.397		
Cardiac disease	1.25 (0.75-2.07) 0.400	1.06 (0.64-1.78) 0.814	1.18 (0.66-2.11) 0.578		
Atrial fibrillation	1.07 (0.54-2.11) 0.847	0.83 (0.42-1.64) 0.585	1.25 (0.52-2.96) 0.620		
Liver disease	0.05 (0.00-169.03) 0.467	0.00 (-) 0.962	0.00 (-) 0.984		
Diabetes	1.39 (0.82-2.36) 0.222	1.35 (0.80-2.30) 0.264	0.97 (0.38-2.47) 0.950		
Hypertension	0.75 (0.45-1.25) 0.272	0.63 (0.37-1.05) 0.077	0.62 (0.33-1.15) 0.126		
Obesity	0.70 (0.36-1.34) 0.277	0.81 (0.42-1.55) 0.521	0.94 (0.47-1.88) 0.861		
Smoking	1.25 (0.54-2.89) 0.609	1.86 (0.75-4.62) 0.183	2.09 (0.79-5.49) 0.136		
Alcoholism	0.54 (0.08-3.92) 0.546	0.60 (0.08-4.45) 0.619	0.40 (0.05-3.07) 0.376		
Chronic medications use					
Diuretics	1.25 (0.74-2.11) 0.397	1.05 (0.62-1.78) 0.855	1.21 (0.67-2.18) 0.527		
Beta blockers	1.00 (0.52-1.92) 0.993	0.96 (0.50-1.84) 0.895	1.14 (0.56-2.35) 0.718		
ACEIs	1.01 (0.58-1.77) 0.974	1.00 (0.57-1.74) 0.987	0.95 (0.50-1.81) 0.887		
ARBs	0.25 (0.06-1.04) 0.056	0.28 (0.07-1.13) 0.073	0.27 (0.06-1.19) 0.084		
Calcium channel blockers	1.05 (0.50-2.22) 0.890	1.05 (0.50-2.20) 0.902	1.22 (0.54-2.73) 0.633		
Statins	0.90 (0.44-1.82) 0.761	1.13 (0.55-2.36) 0.736	1.13 (0.49-2.61) 0.769		
Oral anticoagulants	0.52 (0.19-1.42) 0.202	0.44 (0.16-1.22) 0.117	0.32 (0.09-1.14) 0.079		
Antiplatelet drugs	1.84 (1.04-3.26) 0.036	1.25 (0.73-2.16) 0.418	1.21 (0.61-2.38) 0.592		
Insulin	1.21 (0.55-2.67) 0.631	1.22 (0.55-2.68) 0.628	0.77 (0.30-1.96) 0.584		
Oral antidiabetic drugs	1.44 (0.84-2.47) 0.190	1.89 (1.06-3.38) 0.030	2.69 (1.02-7.07) 0.045		
Inhaled respiratory drugs	0.79 (0.36-1.74) 0.558	0.69 (0.31-1.52) 0.357	0.85 (0.34-2.11) 0.729		
Antineoplastic agents	2.16 (0.68-6.90) 0.193	2.41 (0.76-7.71) 0.137	3.81 (1.00-14.44) 0.049		
Systemic corticosteroids	0.05 (0.00-48.30) 0.389	0.00 (-) 0.969	0.00 (-) 0.980		
NSADs	0.050 (0.00-1882.72) 0.575	0.00 (-) 0.972	0.00 (-) 0.989		
Antihistamines	0.05 (0.00-27.63) 0.348	0.00 (-) 0.967	0.00 (-) 0.977		
Proton-Pump Inhibitors	0.78 (0.46-1.31) 0.345	0.68 (0.40-1.14) 0.145	0.71 (0.38-1.32) 0.278		
Benzodiazepines	1.00 (0.57-1.75) 0.997	1.10 (0.62-1.94) 0.744	0.88 (0.49-1.60) 0.677		
Vaccination's history					
Flu vaccine in prior autumn	2.52 (1.20-5.30) 0.015	2.16 (1.02-4.56) 0.043	2.34 (1.08-5.07) 0.031		
PPV23	0.96 (0.56-1.64) 0.878	0.73 (0.42-1.25) 0.245	0.74 (0.38-1.47) 0.390		
PCV13	0.99 (0.14-7.11) 0.988	0.81 (0.11-5.84) 0.832	1.07 (0.14-8.27) 0.952		
Tetanus	0.61 (0.36-1.01) 0.055	0.64 (0.38-1.07) 0.089	0.66 (0.34-1.27) 0.210		

NOTE: HRs denotes Hazard ratios, and were calculated for those who had the condition as compared with those who had not the condition. In multivariable analysis the HRs were adjusted for age (continuous years), sex, pre-existing comorbidities/underlying conditions, chronic medications use and vaccination's history. Cls denote confidence intervals.